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‘’A scientist in his laboratory is not a mere technician:  
he is also a child confronting natural phenomena that 
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Leishmaniases are parasitic diseases caused by Leishmania parasites, which are 
transmitted to mammals by the bite of sand flies. In the Mediterranean basin, L. infantum 
is the etiological agent of human visceral leishmaniasis, the most severe form of the 
disease. The obvious limitations of current available drugs still provide an undoubtedly 
motivation for research of novel compounds with antileishmanial potential. In the last 
decades, marine organisms or species living in a terrestrial habitat strongly influenced by 
the sea have been shown to be potential sources of rich bioactive compounds. Thus, the 
search for marine natural products with antileishmanial activity has gathered interest and, 
as a result, some promising extracts and compounds have been described. For assessment 
of the in vitro activity of natural extracts mainly axenic promastigotes and amastigotes 
have been used. Although the amastigote-macrophage system remains the ideal model, 
its use has been neglected mainly due to the lack of sensitive and rapid in vitro screening 
methods, which rely on the inherent difficulties of the intracellular stage. In this context, 
the main objective of this work is to contribute for the study of the antileishmanial 
potential of macroalgae and halophytes, through the optimization of screening methods 
focusing on the intracellular amastigote form. The direct counting method was optimized 
and used for the assessment of extracts activity against intracellular amastigotes. 
Concerning the parasite rescue assay, lysis conditions were established. However, 
aberrant results were obtained when the effect of amphotericin B and that of different 
infection ratios was assessed, in comparison to the direct counting method results. As the 
complete optimization of the parasite rescue assay was not possible and reminding the 
shortcomings of the direct counting method, halophyte and macroalgae extracts were 
tested against L. infantum promastigotes. Halophytic extracts were in general inactive 
against L. infantum promastigotes. Spergularia rubra and Inula crithmoides 
dichloromethane extracts were the most active, but were also extremely cytotoxic towards 
THP-1 macrophages. Concerning macroalgae, the hexane and dichloromethane extracts 
of Cystoseira tamariscifolia and the hexane extract of C. usneoides were highly active 
towards the promastigotes with IC50 values below 35 µg mL
-1, yet they had also poor 
selectivity. C. baccata hexane extract was the most selective algal extract (SI > 1.32). 
Additionally, C. baccata and C. barbata hexane:dichloromethane extracts, obtained by 
hot soxhlet extraction, displayed interesting antileishmanial activities (IC50, 50.2 ± 2.6 
and 15.1 ± 2.9, respectively) towards the intracellular stage of L. infantum combined with 
promising SI values (>2.5 and >8.3, respectively), reinforcing the main argument of this 
work that intracellular amastigotes are the ideal in vitro model to be used in drug 
screening purposes, which may yield a larger number of positive hits if implemented in 
future screening efforts.  
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Chapter I – Introduction 




Leishmaniases are parasitic diseases caused by intracellular protozoa parasites 
belonging to the Leishmania genus and transmitted to mammals by the bite of female 
phlebotomine sand flies. At least 20 Leishmania species are known as cause of disease in 
humans and approximately 98 sand flies species, from 800 known, are proven or 
suspected vectors of the human disease (Ezquerra, 2001; Maroli et al., 2013). 
Transmission can be classified as zoonotic or anthroponotic, according to the main 
reservoirs. For example, L. infantum, in the Mediterranean Basin, causes zoonotic visceral 
leishmaniasis, hence the main reservoir is the domestic dog and humans are accidental 
hosts (Ruiz-Fons et al., 2013). L. donovani, in India, causes anthroponotic visceral 
leishmaniasis, where humans play the most important role in the transmission of the 
disease (Singh et al., 2006). 
Concerning human leishmaniasis, these flagellates particularly affect 
mononuclear phagocytic cells and, depending on the parasite species and immune system 
of the host, the disease can have a wide range of clinical forms. However, three basic 
clinical forms of human leishmaniasis are recognized: cutaneous (CL), mucosal (MCL) 
and visceral (VL) leishmaniasis, the latter being also known as kala-azar (Desjeux, 2004; 
Rey, 2011).  
With 350 million people at risk of contracting the disease, the overall prevalence 
of leishmaniasis is estimated to be 12 to 14 million people in tropical, subtropical and 
temperate regions of New and Old Worlds (WHO, 2010a; Ponte-Sucre et al., 2013). It 
occurs in 5 continents and is endemic in 98 countries and 3 territories (Alvar et al., 2012). 
This disease remains a severe public health problem in developed countries, being 
considered by World Health Organization as a neglected tropical disease in developing 
countries (Desjeux, 1996; WHO, 2010a). 
Although human visceral leishmaniasis has been a notifiable disease in 40 
countries since the 1950’s, the number of cases actually occurring is clearly 
underestimated. This can be due to undiagnosed, misdiagnosed or unreported cases, 
discontinuous distribution within endemic areas, lack of diagnostic resources and of 
access to medical healthcare (Desjeux, 2004; Campino et al., 2006; WHO, 2010a).  
In fact, in developing countries poverty and leishmaniasis seem to interact in a 
vicious cycle, where poor house holdings, lack of protective measures, mainly concerning 
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reservoir hosts (e.g., dogs), malnutrition and immunologic deficits, lack of resources and 
of access to health care leads to an increased risk of exposure to leishmaniasis, morbidity 
and mortality. Moreover, impoverished populations encounter many barriers for proper 
treatment of the disease caused by medical debt, disfigurement stigma, work problems 
and poor education. Therefore, its annual incidence is growing in the world’s poorest 
countries (Alvar et al., 2012). 
1.1. Leishmania parasite 
In the beginning of the XIX century, Cunningham and Borovsky were the first to 
describe this parasite, however, Leishman, Donovan, Wright, Lindenberg and Vianna 
identified the parasite and indicated it as the etiological agent of leishmaniasis. In 1903, 
Ronald Ross, attributed the generic name of Leishmania. In 1904, Nicolle was the first to 
name the parasite L. infantum. Four years later described dogs as reservoirs in Tunis and 
was able to maintain an axenic culture in the laboratory (WHO, 2010).  
Leishmania parasites belong to phylum Sarcomastigophora, class 
Zoomastigophora, order Kinetoplastida, family Trypanosomatidae and Leishmania 
genus. However, the classification of Leishmania species has been a controversial. Three 
different categories can be distinguished, according to their development pattern in 
vectors. More specifically, Leishmania species can be considered as hypopylaria if they 
multiply in the pylorus, ileum and rectum bowel of the vector, peripylaria if they 
proliferate in the hindgut or suprapylaria if they divide in the midgut and foregut. This 
theory, described by Lainson et al. (1977), was later supported by phylogenetic studies, 
and has been used until now (Fraga et al., 2010). 
Concerning this classification, Sauroleishmania subgenus belong to the 
hypopylaria group and are considered to be nonpathogenic to mammals, as they 
apparently only infect Old World reptiles upon ingestion of infected phlebotomine sand 
flies. Conversely, in the Viannia subgenus, which includes two main complexes, namely 
L. braziliensis complex (L. braziliensis, L. peruviana) and L. guyanensis complex (L. 
guyanensis, L. panamensis), parasites are classified as peripylaria and pathogenic, as it is 
able to infect mammals as armadillos, sloths, anteaters and also dogs, being restricted to 
the New World (Bates, 2007; WHO, 2010). 
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Lastly, parasites of the Leishmania subgenus are found in the skin, viscera and 
blood of Old World and Neotropical mammals. Parasites from this subgenus belong to 
the suprapylaria group, which is divided in five main complexes: L. donovani complex 
[L. donovani, L. infantum (syn. L. chagasi)], L. tropica complex (L. tropica), L. major 
complex (L. major), L. aethiopica complex (L. aethiopica) and L. mexicana complex (L. 
mexicana, L. amazonensis, L. venezuelensis; WHO, 2010). 
1.1.1. Morphology and Life Cycle 
Leishmania parasites alternate between two morphologic forms (extracellular and 
intracellular) in their life cycle, a consequence of two physiological and biologically 
different environments. The extracellular form, promastigote, develops in the digestive 
tube of the invertebrate host, and the intracellular form, amastigote, in the vertebrate host 
cells of the mononuclear phagocytic system (Kamhawi, 2006). 
Promastigotes have a slender body, about 9 to 15 µm long, multiply actively by 
longitudinal binary fission, and contain a single nucleus and a free flagellum, which 
confers mobility to the cell (Figure 1A,B). Furthermore, as all tripanosomatids, they 
possess a unique subcellular structure with mitochondrial DNA, namely kinetoplast 
(Shlomai, 2004). 
When an infected female phlebotomine sand fly bites a mammal, it lacerates blood 
vessels during feeding and regurgitates parasites (Figure 2). Once in cutaneous 
capillaries, promastigotes are phagocytized by neutrophils, dendritic cells and 
macrophages, migrating into the phagolysosome and differentiating into the non-
flagellated amastigote form. At this point, whether the infected macrophages stay at the 
inoculation site or spread the infection to other organs will determine the progress of 
disease. Oval amastigotes forms, about 5 µm by 3 µm, are obligate intracellular parasites 
with tropism to macrophages, where they multiply. These forms are afflagelate, with a 
large off-center nucleus, the kinetoplast and an axoneme extended to the edge of the 
parasite (Zeibig, 1997; Dedet and Pratlong, 2003; Figure 1B,C).  
 




Figure 1 L. infantum life stages. A) Axenic promastigotes (x400). B) Illustrative 
morphology of promastigote (left) and amastigote (right) forms. a axoneme, b basal body, 
f flagellum, k kinetoplast, n nucleus. C) in vitro intracellular amastigotes inside THP-1 
macrophages (x1000);  
From the moment that parasites enter the bloodstream, neutrophils, natural killer, 
T and B cells work together, trying to eliminate the parasite, by inducing cytokines and 
chemokines production, complement-mediated lysis, nitric oxide (NO) production and 
other leishmanicidal factors. However, Leishmania has the capacity to evade the immune 
response by inducing the activity of suppressive cytokines such as IL-10, synthetizing 
antioxidants as superoxide dismutase and by down-regulating NADPH oxidase and iNOS 
expression, which will reduce or inhibit ROS and NO production (Shio and Olivier, 2010; 
Gupta et al., 2013). Moreover, L. major glycoconjugates such as lipophosphoglycan and 
metalloproteinase gp63 have been pointed as virulence factors for their role in resistance 
to complement mediated lysis (revised by Kamhawi, 2006). 
The parasite multiplies within parasitophorous vacuoles and amastigotes are 
eventually released, when their quantity and damage to the host cell are significant to 
achieve the rupture of macrophages. Released amastigotes will reinvade other 
macrophages, increasing the number of infected cells and extending the infection in the 
mammalian host (Rey, 2011).  
 




Figure 2 The life cycle of Leishmania spp. Inside the vector (right), parasites face the 
process of metacyclogenesis, differentiate into metacyclic promastigotes and migrate to 
the phlebotomine proboscis. When the sand fly bites, it regurgitates promastigotes into 
blood vessels of the mammalian host (left). Promastigotes infect mammalian cells and 
differentiate into oval amastigotes. Amastigotes multiply, lyse the cell and reinvade other 
cells. The phlebotomine sand fly takes a blood meal and ingests amastigotes completing 
and also restarting the cycle (De Assis et al., 2012; Original from Oliveira, M.). 
When a phlebotomine sand fly takes a blood meal, amastigotes are ingested and 
will evolve and multiply in the vector digestive tube, where they transform into procyclic 
promastigotes (Figure 3; Ezquerra, 2001; Rey, 2011). 
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Inside the vector, metacyclogenesis begins with the transformation of amastigotes 
into small procyclic promastigotes with short flagella, which will further develop into 
larger, slender forms, called nectomonads, within 2-3 days (Figure 3).  
At day 4, leptomonads are formed from nectomonads and by day 5-7 differentiate 
into metacyclic forms. Leptomonads produce a promastigote secretory gel (PSG) which 
will comprise the last promastigote forms mentioned, in the thoracic midgut. Metacyclic 
forms are small cells with an elongated flagellum, highly motile and are the infective 
stage to the mammalian host. The latter forms will accumulate at the stomodeal valve, 
being available for transmission. When a phlebotomine sandfly bites a mammalian host, 
the cycle restarts (Kamhawi, 2006). 
All Leishmania species are morphologically indistinguishable, with high 
structural homogeneity in all stages of their biological life cycle. The differentiation of 
these parasites used to rely in extrinsic characteristics such as type and location of the 
primary lesions they cause in humans, type of hosts and geographic distribution (Bogitsh 
and Cheng, 1998; Ezquerra, 2001).  
Nowadays, with the advances in molecular methods, Leishmania parasites are 
identified based in intrinsic characteristics, such as its genome, which allow the 
identification of the species, subspecies and variants. 
Analysis of isoenzymes by electrophoresis (multilocus enzyme electrophoresis - 
MLEE) is currently the gold standard technique for species identification and genus 
taxonomy. Performed by only few reference laboratories, it has limitations as the 
requirement to isolate parasites in culture (Chargui et al., 2012).  In this technique, strains 
with the same enzymatic profiles are grouped, creating a taxonomical unity called 
zymodeme. In the Mediterranean basin, L. infantum MON-1 is the principal zymodeme 
responsible for the majority of VL cases (Pratlong et al., 2004; Campino et al., 2006).  
It has already been reported variations in the response for treatment by various 
species, emphasizing the importance of a correct species identification for the appropriate 
and effective treatment (Arevalo et al., 2007; Tiuman et al., 2011).  




Figure 3 Schematic representation of the development of Leishmania parasites inside the 
phlebotomine sandfly vector (Adapted from Kamhawi, 2006). 
1.2. Vectors and Reservoirs 
Phlebotomine sand flies belong to class Insecta, subclass Pterygota, order Diptera, 
suborder Nematocera, family Psychodidae and subfamily Phlebotominae. They are small, 
have blade-shaped hairy wings and when at rest they are easily identifiable because of 
their pointed wings at an angle above the abdomen (Dedet and Pratlong, 2003).  
Sand flies can be found in various habitats from dry regions as deserts and 
savannas to tropical rain forests. They prefer to rest during the day, at dark places such as 
henneries, rodent burrows, wall holes and cracks as well as human dwellings and become 
active at dusk and during the night. Only female phlebotomine sand flies are 
hematophagous, as they need blood to provide nutrients for the maturation of their eggs 
(Lane and Crosskey, 1993; Dedet and Pratlong, 2003; WHO, 2010).   
The geographic distribution of leishmaniasis reflects the presence or absence of 
parasite species and their respective vector species. From five genera accepted there are 
two with epidemiologic and medical importance, which all the proven vectors of 
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leishmaniasis. They include: Lutzomyia genus, in the New World and Phlebotomus genus, 
vectors in the Old World (Dedet and Pratlong, 2003; Rey, 2011).  
Although many authors mention that some species of the Sergentomyia genus 
have no medical importance some reports have questioned this dogma. S. minuta and S. 
darling were both found naturally infected with L. major in Portugal and Mali, 
respectively. These reports suggest that if its anthropophilic behavior is proved, these 
species may play a potential role in the transmission of leishmaniasis and probably other 
vector borne diseases (Campino et al., 2013). 
The efficacy of parasite transmission by sand flies depends on intrinsic factors of 
the vector such as longevity, density, trophic preferences and exo/endophilic 
characteristics, the proximity of their preferential reservoirs and the responsiveness of 
human infection (Ezquerra, 2001). 
In relation to Leishmania’s reservoirs, in the Mediterranean basin, Latin America 
and some parts of China, the domestic dog is the most important one. Concerning L. 
infantum, the dog is considered as the only primary reservoir of infection.  Dogs seem to 
be an ideal reservoir, as they become regularly infected, often presenting high parasite 
loads, which favors parasite transmission. They also share the same environment with 
humans, favoring the maintenance of disease. Interestingly, the most common zymodeme 
of L. infantum (MON-1) is also predominantly isolated in dogs (Dantas-Torres, 2007; 
Diniz et al., 2008; Rey, 2011). 
Besides the visceral manifestations, cutaneous lesions are the most common 
effects of canine leishmaniasis (CanL) that can be accompanied by loss of body weight 
and appetite, fever and diarrhea (Solano-Galego et al., 2011). Some accidental reservoirs 
have been referred in the literature such as horses (Rolão et al., 2005), goats, buffaloes 
and cows (Bhattarai et al., 2010) but recently, some authors have been reporting cases of 
leishmaniasis in domestic and peridomestic cats in Portugal (Maia et al., 2010), Italy (Poli 
et al., 2002), Brazil (Savani et al., 2004) and France (Ozon et al., 1998), emphasizing the 
potential role of cats as natural reservoirs and in the epidemiology of disease. 
Besides domestic reservoirs wild animals as well as non-domestic canidae, 
rodents and hyraxes are the main wild reservoir hosts in the Old World while opossums, 
sloths, anteaters, non-domestic canidae and rodents are important reservoirs in the New 
World (WHO, 2010). 
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1.3. Epidemiology and clinical forms of the disease 
The outcome of infection varies depending on complex interactions between 
virulence, tropism and pathogenicity of the infecting species and the immune response of 
the mammalian host (Mandell et al., 2004). Although a species can produce more than 
one of these clinical forms there is a predisposition for particular species to cause a certain 
disease phenotype (Table 1).  
VL is a systemic disease mainly caused by two species: L. donovani and L. 
infantum (syn. L. chagasi; Assimina et al., 2008). From 0.5 million new cases that are 
estimated to occur annually in 65 countries, 90% of these are found in Bangladesh, Brazil, 
India, Nepal and Sudan, affecting both children and adults (WHO, 2010). 
In this clinical form, the parasite has a tropism for internal organs, in particular 
the spleen, liver, bone marrow and lymph nodes. Most common clinical manifestations 
are undulating fever, weight loss, loss of appetite, spleno- and hepatomegaly. VL is 
considered the most severe form of disease, being potentially fatal if left untreated, with 
a mortality rate of almost 100% (Ezquerra, 2001; Assimina et al., 2008; Sharma and 
Singh, 2008).  
Post-kala-azar dermal leishmaniasis (PKDL) is a complication of VL that usually 
develops 6 months to 1 or more years after apparent cure or in the absence of VL history. 
Its incidence is almost restricted to endemic areas of L. donovani, namely the Indian 
subcontinent and Sudan, where frequency of the condition is about 50-60% and 5-10%, 
respectively (Zijlstra et al., 2003; WHO, 2010; Ganguly et al., 2010). 
CL, the most common form of human leishmaniasis, is a rarely fatal disease that 
is characterized by well-delimited skin lesions with elevated borders and it is estimated 
that its annual incidence is 1–1.5 million cases per year (Desjeux, 2004). The majority of 
cases are self-healing, although some lesions can persist and leave scars with variable 
size. A rare form of CL is diffuse cutaneous leishmaniasis (DCL) in which patients may 
have multiple mixed type skin lesions (non-ulcerative) in several parts of their body, 
within a short period of time since the appearance of the first lesions. It is difficult to treat, 
spontaneous cure is rare and can have devastating consequences to the individual (Turetz 
et al., 2002).  
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Table 1 Most clinically relevant Leishmania species, respective vectors, main geographic 
distribution and clinical features (Barral et al., 1991; Ziljstra et al., 2003; Reithinger et 
al., 2006; Alborzi et al., 2006; Akilov et al., 2007; Amato et al., 2008; Badirzadeh et al., 
2013). 
VL, Visceral leishmaniasis; CL, Cutaneous leishmaniasis; DCL, Diffuse cutaneous leishmaniasis; MCL, 
Mucocutaneous leishmaniasis; PKDL, Post-kala-Azar dermal leishmaniasis. *common; ** rare; *** very 
rare. 
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L. (L.) amazonensis Amazon basin, Brazil 
CL*, DCL**, 
MCL**, VL*** 
L. (L.) venezuelensis Venezuela CL* 
L. (V.) braziliensis 




L. (V.) panamensis 
Panama, Costa Rica, 
Colombia 
CL*, MCL* 




L. (V.) peruviana Peru and Argentina CL* 
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MCL or espundia can be caused by various species. However, L. braziliensis is 
responsible for the majority of cases and, consequently, geographic distribution of this 
manifestation is almost restricted to South America. Severe MCL cases can lead to facial 
disfiguration, which is never self-healing, being difficult to manage and thus potentially 
fatal (Reithinger et al., 2006; Amato et al., 2008). 
1.3.1. Leishmaniases in Portugal 
 The first autochthonous case of leishmaniasis in Portugal was described by 
Alvares (1910), referring to a 9-year-old female. A year later, the same author reported 
the occurrence of CanL in Lisbon, detecting an incidence of 2.66% upon examining 300 
dogs. However, no infection was found, in the 58 cats screened (Alvares and Silva, 1911). 
Since these reports, additional studies have been carried out in Portugal, 
describing the prevalence of VL, CanL and unraveling the bioecology and distribution of 
the vectors (Abranches et al., 1993; Cardoso, 2004a, 2004b; Marques, 2008; Branco et 
al., 2013; Sousa et al., 2011; Cortes et al., 2012). 
L. infantum is the major responsible for the VL cases in Portugal, although few 
cases of CL caused by this species were also diagnosed in Portuguese adults and children. 
Concerning phlebotomine sand flies, besides of only P. perniciosus and P. ariasi are the 
confirmed vectors of L. infantum, P. papatasi, P. sergenti and S. minuta are known to 
also occur in the country (revised by Campino et al., 2006; Cortes et al., 2007; Campino 
and Maia, 2010). 
 VL cases in the Mediterranean basin usually affect pediatric patients less than 4 
years old and human immunodeficiency virus (HIV) co-infected individuals (Kafetzis, 
2003; WHO, 2010). In fact, in Southern Europe, 70% of VL cases in adults are related to 
HIV-positive individuals, especially among intravenous drug users. Most probably 
needle-sharing has inadvertently created an alternative cycle of transmission, putting this 
population at risk for contracting the disease (Cruz et al., 2006). In Portugal, the Lisbon 
Metropolitan Area is considered to be a focal point of the disease, where most cases in 
humans have been reported, especially due to HIV co-infection, as previously mentioned 
(Campino and Maia, 2010).  
 Between 2000 and 2006, 152 new cases of VL were diagnosed in the Unidade de 
Leishmanioses, IHMT (26% in immunocompromised individuals), but in the same 
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period, only 86 cases of VL were notified to Direcção Geral de Saúde, 74 of which 
occurring in the Lisbon Metropolitan Area (Cortes, 2008).  However, between 1999 and 
2009, only 145 cases of VL were notified through the mandatory disease declaration 
system (Serrada, 2010). Thus, these data suggest that the number of actual cases may be 
underestimated. 
 CanL is endemic in the Mediterranean basin being considered a serious public 
health problem mainly due to subclinical infections that delay the diagnosis favoring the 
maintenance and transmission of disease (Solano-Galego et al., 2011). The situation of 
CanL in Portugal is more disturbing than of human leishmaniasis. Three regions, namely, 
Alto Douro, Lisbon and Algarve, are known endemic foci of CanL. In some localities 
such as Alijó, the prevalence of infection can reach up to 20% (Campino et al., 2006). In 
a study performed by Cortes et al. (2012), the dog’s age, fur size, district and living 
outdoors were the risk factors identified for CanL in Portugal. Moreover, in the same 
study, higher seroprevalence was found in districts from the interior of Portugal, namely 
Castelo Branco, Beja and Portalegre, in comparison to coastal regions (Cortes et al., 
2012).  
Considering the biological cycle of Leishmania parasites, an increase in CanL 
cases should not be take too lightly, because it can foretell an increase in human visceral 
leishmaniasis cases.  
1.4. Current available and under development drugs for leishmaniases 
treatment 
The control of this vector-borne disease relies mostly in chemotherapy till date. 
However,  current available drugs for human leishmaniasis treatment exhibits several 
disadvantages such as high costs, toxicity, long-term periods of parental administration 
for some drugs, variation in intrinsic sensitivity between Leishmania species and 
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Table 2 First and second-line drugs used against leishmaniases and their possible or 
established mode of action (Saha et al., 1986; Vercesi and Docampo, 1992; Maarouf et 
al., 1995; Balaña-Fouce et al., 1998; Sereno et al., 2001; Sudhandiran and Shaha, 2003; 
Bray et al., 2003; Paris et al., 2004; Verma and Dey, 2004; Chawla et al., 2011; Fernández 
et al., 2011; Carvalho et al., 2011). 
Drug Mode of Action 
Pentavalent antimonials  
Conversion to its toxic trivalent (SbIII) form within 
macrophage inhibits trypanothione reductase and exposes 
parasite to oxidative stress. DNA fragmentation, PS 
externalization, ROS generation, and increase of Ca2+ 
levels were observed. 
Miltefosine 
Unclear. Induces apoptosis-like cell death – based on 
observed phenomena like cell shrinkage, DNA 
condensation and fragmentation and PS externalization. 
Pentamidine 
Unclear. Disintegration of kinetoplast and mitochondria 
and collapse of the mitochondrial membrane potential were 
observed. 
Amphotericin B  
High affinity to ergosterol in Leishmania membrane, 
forming channels-like pores leading to permeability of the 
membrane and causing parasite death. 
Paromomycin 
Inhibits protein synthesis by targeting proteins involved in 
translation, particularly ribosomal proteins. 
Sitamaquine 
Acts against the respiratory chain – based on observed 
phenomena like induced depolarization of membrane 
potential, increased ROS production, increased Ca2+ levels 
and PS externalization.  
PS – Phosphatidylserine; ROS – Reactive oxygen species 
For more than 60 years, pentavalent antimonials compounds (Sbv), sodium 
stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®), remained as 
first line drugs of choice against all forms of leishmaniasis, although their action 
mechanisms are still unclear (Singh et al., 2012; Table 2). Intrinsic variation between 
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Leishmania species have been pointed out as the reason for variation in clinical response 
to Sbv treatment. As revised by Croft et al. (2006), L. braziliensis and L. donovani seem 
to present higher sensivity to Sbv than L. tropica, L. major and L. mexicana. 
First reports of pentavalent antimonials resistance came from Bihar, India in 
1980’s when patients were not responding to the treatment. Nowadays, half of the global 
cases of VL occur in North Bihar and India, which is considered as an endemic area 
displaying high drug resistance, mainly due to inadequate dosage or incomplete treatment 
duration (Sundar, 2001; Tiuman et al., 2011). Nowadays, second-line drugs include 
miltefosine, amphotericin B (AmB) and pentamidine. 
In 2014, miltefosine (Impavido®) was approved by Food and Drug 
Administration (FDA) to treat the three main forms of leishmaniasis, but especially VL 
caused by L. donovani (FDA, 2014). Regardless of its dual effectiveness, it has the 
disadvantage of requiring a long period of administration with some side effects such as 
vomiting and diarrhea with occasional hepatic and renal toxicity, which can lead to 
abandonment of treatment and non-compliance by patients. Moreover, because of its 
teratogenicity, it is not suitable for pregnant women (Singh et al., 2012; Ponte-Sucre et 
al., 2013).  
Miltefosine also showed to be well tolerated and therapeutically efficient against 
CanL, in a clinical trial with L. infantum infected dogs from the Mediterranean basin 
(Woerly et al., 2009). Still, the increase of its off-label use to treat CanL, in Europe, may 
lead to L. infantum parasite’s resistance. 
AmB is an antifungal drug with high affinity to ergosterol, the main sterol in 
fungal and tripanosomatids cell membrane, that is used in endemic areas with parasite 
resistances reported (Singh et al., 2012). In Europe, AmB is widely used as drug of choice 
in the treatment of visceral cases, especially in pedriatic and HIV co-infected individuals 
(Maia et al., 2009).  Due to side effects such as fever and renal complications of AmB, 
liposomal formulations of AmB have been developed and proved to be highly efficient. 
However, its high costs limit their application (Singh et al., 2012). 
Phase II clinical trials in India and Africa suggested that the oral drug sitamaquine 
was effective and well tolerated for treatment of VL, despite some mild adverse effects 
reported, such as vomiting, dyspepsia, cyanosis, nephritic syndrome, glomerulonephritis, 
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abdominal pain, headache and severe renal dysfunction (Jha et al., 2005; Wasunna et al., 
2005).  
Paromomycin is an aminoglycoside that may have ribosomes of Leishmania as its 
primary cellular target (Maarouf et al., 1995). A combination of gentamicin and 
paromomycin for topical use against CL was evaluated in phase III clinical trials, and the 
use of both paromomycin with or without gentamicin was efficient (Ben Salah et al., 
2013). 
In addition to the drugs here described, the number of patents for antileishmanial 
compounds has dramatically increased since 1980’s up to now. However, because of the 
shortcomings listed above, there is still an urgent need of novel, less toxic, more 
affordable and effective anti-Leishmania drugs with short-term administration periods 
that can be used alone or in combination with other therapies (Monzote, 2011). 
2. Natural Products in Drug Discovery  
The term natural product (NP) refers usually to secondary metabolites produced 
by living organisms, which are generally derived biosynthetically from primary 
metabolites (lipids, aminoacids) and are not essential to growth, development and 
reproduction of the living organism, but they may influence ecological interactions 
between these and the environment where they are inserted (Buchanan et al., 2000).  
NP have extensively been studied in the past decades for their biological activities 
for medicinal, recreative and nutritional applications (Ramawat and Mérillon, 2008). 
Plants have always been a rich source of NPs are still being used in traditional medicine 
for their medicinal properties mainly in developing countries from Africa, Latin America 
and Asia, and ethnobotanic studies have been carried to support the discovery and 
development of new drugs (Valentin et al., 2000; Sheng-Ji, 2001). 
Interestingly, the antiparasitic potential of plants used in traditional medicine has 
been investigated. The most successful case is Artemisia annua, a plant that has been used 
for more than two thousand years in China’s traditional medicine as a remedy for fever. 
It has been shown that its major active compound, artemisinin, can be used efficiently 
against malaria, avoiding many deaths since mid-70s until now (Woerdenbag et al., 
1990).  
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Apart from the diversity of terrestrial plants, water covers 70% of our planet and 
in some ecosystems the biodiversity is higher than that in rain forests. Therefore the 
potential of marine organisms, such as invertebrates and algae, has been recognized as 
sources of novel drug leads (Haefner, 2003).  
In the last decade, over than 5,000 structures of marine natural products have been 
described, many with potential to be applied in several fields (Sarker et al., 2006). Still, 
more than 1,000 molecules have already been developed, some of which are currently 
under clinical evaluation for the treatment of cancer (Newman and Cragg, 2004), 
Alzheimer’s disease (Won Kim et al., 2007) and other ailments.  
Marine natural products have been obtained from cyanobacteria, actinomycetes, 
fungi, algae, sponges, corals and ascidians. Between 2008 and 2010, from the 133 
antiparasitic small molecules analyzed with an inhibitory concentration of 50% (IC50) 
below 30 µM, 87 apparently derived from marine sponges (Watts et al., 2010). 
According to Mayer et al. (2011), between 2007 and 2011, sixteen studies of 
marine products contributed to novel findings in antiprotozoal pharmacology. Six studies 
focused on Leishmania spp. with an IC50 between 0.093 and 12 µg mL
-1 (Mayer et al., 
2011; 2013). 
Although many studies have been focusing in screening marine organisms and 
promising results have been published, only few antiprotozoal compounds have been 
identified in the last decades (Watts et al., 2010). 
2.1. Algae as source of antileishmanial compounds 
There are about 30,000 species of algae all over the world and approximately 
13,000 are macroalgae. These are usually distinguished morphologically on the basis of 
the thallus colour: red (phylum Rhodophyta), green (phylum Chlorophyta) and brown 
(phylum Ochrophyta) algae (Bhakuni and Rawat, 2005; Hayes, 2012). 
Macroalgae are exposed to several abiotic and biotic stresses and so their bioactive 
compounds have evolved as chemical weapons in response to adversities. Therefore they 
may show multiple functions and biological activities (Hayes, 2012). 
Several studies have demonstrated the potential of seaweeds bioactive metabolites 
with anticancer (Hussain et al., 2012), antioxidant (Vadlapudi, 2012), anti-inflamatory 
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(Lee et al., 2013), antifungal (Cosoveanu et al., 2010), antibacterial (Tuney et al., 2006), 
antiprotozoal (Allmendinger et al., 2010) and antifouling (Manilal et al., 2010) activities.  
Recently, investigators have screened many algae from all over the world against 
different species and stages of Leishmania (Table 3).  
In these studies, the same algal species from different places presented diverse 
antileishmanial activities, possibly due to different metabolites that are produced in 
response to different environment conditions (Orhan et al., 2006; Spavieri et al., 2010b). 
The majority of the reports that studied antileishmanial activity, characterized the 
activity of crude extracts and very few have been tested in their pure form, namely against 
L. amazonensis (Dos Santos et al., 2010; Da Silva Machado et al., 2011; Dos Santos et 
al., 2011; Soares et al., 2012). The identified compounds are the sesquiterpene elatol, 
isolated from the red alga Laurencia dendroidea (Dos Santos et al., 2010), the 
sesquiterpene obtusol also from L. dendroidea (Da Silva Machado et al., 2011), the 4-
acetoxy-dolastane diterpene obtained from the brown alga Canistrocarpus cervicornis 
(Dos Santos et al., 2011) and the dolabellene diterpene dolabelladienetriol, purified from 
the brown alga Dictyota pfaffii (Soares et al., 2012). All presented remarkable IC50 values 
and curiously, dolabelladienetriol, besides inhibiting the growth of L. amazonensis 
promastigotes and intracellular amastigotes, it also reduced the parasite growth during 
HIV co-infection (Soares et al., 2012). Also, in these studies, different parasite forms 
demonstrated different susceptibilities to the same algal extract, highlighting the 
importance of a suitable in vitro model.   
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Table 3 Marine algae species with antileishmanial activity and IC50 below 20 μg mL
-1. 
(Adapted from Vizetto-Duarte et al., in press). 
Macroalgae species Leishmania spp. Parasite stage 
Codium fragile ssp. Tomentosoides L. donovani AA 
Ulva intestinalis L. donovani AA 
Ulva lactuca L. donovani AA 
Bifurcaria bifurcata L. donovani AA 
Cystoseira baccata L. donovani AA 
Cystoseira tamariscifolia L. donovani AA 
Halidrys siliquosa L. donovani AA 
Dictyopteris polypodioides L. donovani AA 
Dictyota dichotoma L. donovani AA 
Turbinaria turbinata L. mexicana P 
Laurencia microcladia L. mexicana P 
Ceramium rubrum L. donovani AA 
Halopitys incurvus L. donovani AA 
Dilsea carnosa L. donovani AA 
Scinaia hatei L. major P 
Laurencia pinnatifida L. major P 
Bostrychia tennela L. mexicana P 
AA – axenic amastigotes; P – promastigotes 
 
2.1.1. Brown macroalgae belonging to the Cystoseira genus 
The family Cystoseiraceae (Order Fucales) have a wide distribution in the 
Northern Hemisphere. Nevertheless, from 292 of brown algae species known belonging 
to the Cystoseira genus, 80% occur along the Mediterranean and Atlantic coasts (Garreta 
et al., 2001; Guiry and Guiry, 2014). 
In Portugal, the most common species are C. baccata, C. humilis, C. nodicaulis, 
C. tamariscifolia and C. usneoides (Garreta et al., 2001). 
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Since 1984, Cystoseira spp. have been chemically studied extensively. Its 
chemical profile characterization revealed mainly diterpenoids (Ayyad et al., 2003), 
meroditerpenoids (De Los Reyes et al., 2013), tetraprenyltoluquinol derivatives (Fisch et 
al., 2003), fatty acids, sterols (Andrade et al., 2012) and terpenes (Kamenarska et al., 
2002). 
Considering its chemical constitution, Cystoseira species have been investigated 
for their pharmaceutical potential and among those studies extracts from these algae were 
shown to possess antibacterial  (Bennamara et al., 1999; Süzgeç-Selçuk et al., 2010; 
Spavieri et al., 2010a), antifungal (Bennamara et al., 1999), antiprotozoal (Spavieri et al., 
2010a; Süzgeç-Selçuk et al., 2010), antioxidant (Fisch et al., 2003; Mhadhebi et al., 
2011), cytotoxic (Ayyad et al., 2003; Spavieri et al., 2010b), antiviral (Urones et al., 
1992), anti-tumoural (Urones et al., 1992) and anti-inflammatory (Mhadhebi et al., 2011; 
De Los Reyes et al., 2013) activities. 
Nevertheless, few papers that evaluate the antileishmanial activity of novel 
Cystoseira species have been published. For example, C. baccata, C. tamariscifolia, C. 
barbata and C. crinita extracts have been shown to be active against L. donovani axenic 
amastigotes (Spavieri et al., 2010b; Süzgeç-Selçuk et al., 2010). Only two studies have 
evaluated the potential of macroalgae from the Cystoseira genus against L. infantum 
(Bruno de Sousa et al., 2012; Ainane et al., 2014). 
The published results together with the availability and biodiversity of the 
Cystoseira species in the Iberian Peninsula suggest that this genus is a potential source of 
antileishmanial compounds. 
2.2. The pharmacological potential of halophytes 
Halophytes are a group of plants that can tolerate high salinity levels, occurring 
in a variety of environments such as sand dunes, rocky coasts, saline depressions or inland 
deserts but also in locations with sea influence, such as coastal regions, salt marshes and 
mudflats (Ksouri et al., 2012a). 
There are about 2,600 species of halophytes, 700 of which occurring in the 
Mediterranean flora (Beligno and Sardo, 2008).  Besides being a relative small group of 
plants, the research on their biological metabolites remains quiet unexplored. Because of 
the extreme conditions that they encounter in their habitats (salinity, drought, UV light), 
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halophytic plants have developed several biochemical defenses by biosynthesizing a 
variety of bioactive compounds such as polyphenols (Ksouri, 2012b) saponins, flavonoids 
and sterols (Ksouri et al., 2013). 
Also in response to biotic and abiotic stress, halophytes may accumulate high 
levels of ROS, which can lead to cell damage. However, their potent antioxidant system 
is able to overcome and quench toxic ROS, suggesting that this may be an environmental 
adaptation (Ksouri et al., 2012b; Mohammed et al., 2013). Thus, several studies have 
reported the antioxidant potential of halophytes.  
Recently, five halophyte species from southern Portugal demonstrated powerful 
antioxidant, anti-inflammatory and anti-tumoral activities (Rodrigues et al., 2014). 
Furthermore, Arthrocnemum macrostachyum and Carpobrotus edulis have been 
described as powerful sources of compounds against degenerative and neurological 
disorders such as Alzeihmer’s disease (Custódio et al., 2012).   
Other biological activities have been reported such as antibacterial (Ibtissem et 
al., 2012), antifungal (Samiullah and Bano, 2011), antifouling (Kong et al., 2014), 
antiobesity (Kalai et al., 2013) and antidiabetic (Chikhi et al., 2014).  
Besides some halophytes species are described in the literature as used in folk 
medicine to treat parasitic diseases, no published studies exploring the activity of 
halophyte extracts or derived compouds towards L. infantum parasites were found 
(Farooq et al., 2008). However, only a panel presentation studied the antileishmanial 
activity of Carpobrotus edulis, Juncus acutus and Convolvulus soldanella (Bruno de 
Sousa et al., 2013). 
In conclusion, reports concerning the antiparasitic activity, more specifically 
antileishmanial activity are scarce. Nevertheless, their pharmacological potential against 
Leishmania spp. should not be ignored, having in mind their biodiversity, availability and 
the wide range of demonstrated bioactivities. 
3. In vitro screening of natural products with antileishmanial activity  
Plants and marine organisms possess several compounds in its constitution. Thus, 
the isolation of NP can be time-consuming, laborious and also may depend on the 
separation techniques and solvents used (Sticher, 2008).  
Diverse extraction methods can be applied, according to the compounds of interest 
and the aim of its isolation (Cannel, 1998). A critical first step in NP isolation is the 
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preparation of extracts, complex mixtures of compounds, using different organic solvents 
(e.g., hexane, acetone, dichloromethane, methanol, ethanol; Tempone et al., 2011).  
Different solvents will extract different compounds, according to the solvents’ 
polarity and the compounds solubility, which may affect its bioactivity. For example, the 
use of 80% acetone (ACE) is suggested to extract a higher concentration of phenolic 
compounds instead of 80% methanol (MeOH) and ethanol extraction, which reflects in 
the antioxidant activity of the extracts (Zhao et al., 2006; Taha et al., 2011). Moreover, 
more polar solvents will extract hydrophilic compounds and, in contrast, lypophilic 
compounds can be extracted using, for example, dichloromethane (Cos et al., 2006).  
Thus, the selection of the extraction method is of major importance to an efficient 
in vitro screening of antileishmanial activity. Despite the simple procedures of 
conventional extraction methods, such as percolation, maceration and Soxhlet-based 
extractions, these may present several drawbacks like the need for large amounts of 
solvents, being time-consuming and leading to differences in extraction efficiency 
(Sticher, 2008). Also, it is essential to avoid the lost or degradation of volatile and labile 
compounds, during the preparation of extracts that can be potentially active (Cos et al., 
2006; Sticher, 2008).  
The primary screening approach to identify the potential of extracts as source of 
antileishmanial compounds include two essential techniques: determination of the 
antileishmanial activity and cytotoxicity. Usually, the efficiency of bioactivity of an 
extract is evaluated by the IC50. Therefore, an interesting extract will exhibit a high 
activity against the parasite and low toxicity against cells, based on the IC50 values, being 
considered selective against Leishmania parasites. 
Moreover, as the compound(s) responsible for the activity observed against 
Leishmania parasites may differ from the one responsible for the cytotoxicity, some 
authors only evaluate the cytotoxicity of the selected fraction(s) or compound (s), after 
bio-guided fractionation studies (De Toledo et al., 2014).  
Once the extract demonstrates to possess active and selective compounds against 
Leishmania parasites, it can be fractioned and the activity of each fraction assessed until 
a pure fraction, containing the active compound(s), is obtained. Extracts and fractions 
must be tested at a maximum concentration of 300 µg mL-1 and isolated compounds at 
maximum of 100 µg mL-1 in order to avoid false selection of poorly active compounds 
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(Tempone et al., 2011). However, it has been proposed that concentrations higher than 
150 µg mL-1 usually cause an increase in false positive (Cos et al., 2006). 
The main difficulty of researching novel antileishmanial compounds still lies on 
the lack of sensitive, rapid and standardized screening methods. Nowadays, different 
techniques are being used, focusing on axenic promastigotes, amastigotes and 
intracellular amastigotes (Spavieri et al., 2010a; Jain et al., 2012; Feily et al., 2012). 
3.1. Parasite and cellular models for in vitro assays  
In vitro assays focusing on the promastigote stage are widely used for preliminary 
screens mainly due to its simple maintenance in laboratory. Moreover, the screening 
method usually requires little amounts of extracts and fractions and do not require 
sophisticated equipaments, allowing the test of several samples simultaneously (Tempone 
et al., 2011).   
However, the use of the promastigotes form in screening assays has been 
controversial since it is the extracellular form, mainly found in the phlebotomine vector, 
requires different environmental conditions than those for amastigotes. Consequently, is 
considered that it may not be a suitable in vitro model (Gupta and Nishi, 2011). 
Supporting this idea, a high percentage of compounds that were active against 
promastigotes were found to be inactive against intracellular amastigotes and vice versa, 
resulting in false positive and false negative results (Siqueira-Neto et al., 2010; De 
Muylder et al., 2011).  
Axenic amastigotes are also easy to maintain in cultured suspensions in 
laboratory. Because of its similarity to the relevant stage of the parasite, these have been 
pointed out as promising in vitro models for drug screening. However, the activity against 
axenic amastigotes can be underestimated since it does not consider either the extreme 
intracellular conditions inside the macrophage or the compound penetration into the host 
cell (Gupta and Nishi, 2011; Tempone et al., 2011; Bringmann et al., 2013). For instance, 
naloxonazine was found to be active against intracellular amastigotes but inactive against 
both axenic forms of L. donovani, suggesting that its activity may be dependent of the 
presence of the host cells (De Muylder et al., 2011). In addition, compounds active against 
axenic amastigotes can be inactive against intracellular forms, due to the inability of these 
compounds to penetrate the macrophage membrane or to withstand the acidic 
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environment inside the host cell (De Muylder et al., 2011). Thus, the presence of the host 
cell could be important to precise the drug-mediated toxicity towards the intracellular 
parasites (Sereno et al., 2007). 
Not surprisingly, the use of both axenic forms have been questioned mainly due 
to relevant differences in cellular, physiological, biochemical and molecular levels when 
compared to intracellular forms (Jain et al., 2012). 
In contrast, intracellular amastigotes are obtained by in vitro infection of 
mammalian cell lines with the parasite. Concerning its mammalian host, Leishmania 
infect mononuclear phagocytic cells, mainly differentiated macrophages. These descend 
from monocytes recruited from blood, being a crucial component of the innate immune 
response (Vannier-Santos, 2002; Daigneault et al., 2010). Thus, various cellular types are 
used as host cells such as murine peritoneal macrophages or human-monocyte 
transformed macrophages such as L6, THP-1 and J774, available as continuous cultures. 
As the latter are monocytic cellular lines, they require differentiation into macrophages 
and loss of proliferation, to assure that are no confounding effects when activity of the 
compound is assessed (Ioset et al., 2009; Gupta and Nishi, 2011).  
To achieve differentiation stimuli such as phorbol-12-myristate-13-acetate (PMA) 
have been used. PMA is a phorbol ester, activator of protein kinase C that is widely used 
to induce cell differentiation, hence it increases adherence and expression of surface 
markers and promotes the loss of proliferation, associated with macrophage 
differentiation (Schewnde et al., 1996; Daigneault et al., 2010). 
Recently, the comparison between the antileishmanial activities of four standard 
drugs against intracellular amastigotes of L. donovani highlighted the influence of the 
type of host cell used and in vitro activity observed (Seifert et al., 2010). 
3.2. Methods applied to antileishmanial drug discovery 
Cell viability based assays, such as resazurin or 3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide (MTT), are the most commonly used assays in a laboratory 
setting to evaluate antileishmanial activity in parasite axenic forms or cytotoxicity against 
host cells. This is mainly due to their low costs, accuracy and the ease with which dose 
response curves can be obtained (Tempone et al., 2011). The principle of these assays 
relies on the metabolization of the active compounds (resazurin, MTT) by viable cells, 
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which enables the fluorimetric and/or colorimetric quantification of the percentage of 
viable cells. 
Classical methodologies for the evaluation of antileishmanial activity of 
compounds in intracellular amastigotes include direct counting assays after stained 
smears and the determination of the inhibitory concentration values, based on the 
percentage of infected cells or number of amastigotes per macrophages counted (Sereno 
et al., 2007). This method remains the standard procedure. However, it has several 
drawbacks such as being time-consuming, laborious and may provide subjective 
operator-dependent microscopic counts that can lead to inaccurate evaluations. Moreover, 
these techniques are usually used to assess the activity of compounds which demonstrated 
previously to be active against axenic forms (Fumarola et al., 2004; Tempone et al., 2011).   
For years, several attempts were made to develop an ideal method for screening 
against the clinical relevant stage, including labelling parasites with monoclonal 
antibodies (Guinet et al., 2000) and with radioactive uracil nucleotides (Berman and 
Gallalee, 1985). However, the significant short-comings of these techniques, mainly high 
costs and the use of radioactive nucleotides may represent a potential risk for workers, 
which have led to their scientific oblivion (Sereno et al., 2007). 
More recently, Jain et al. (2012) described a new fluorimetric method based in 
parasite rescue of L. donovani intracellular amastigotes. Briefly, after infection of 
differentiated THP-1 cells and treatment with reference drugs, a critical step is the lysis 
of the macrophages with sodium dodecyl sulfate (SDS) and mechanic agitation of the 
plate, enabling the release of intracellular amastigotes. After this step, plates are incubated 
for amastigotes to return to the promastigote form and its viability is evaluated with the 
commercial resazurin-based kit, Alamar Blue® (Jain et al., 2012). 
Resazurin is a blue dye, used as a cell viability indicator which is reduced by 
viable cells to the fluorescent dye, resorufin (O’Brien et al., 2000). This dye has gain the 
interest due to its appealing advantages. Resazurin is relatively non-toxic to cells, less 
expensive, allows the choice of the detection method (colorimetric/fluorimetric) and does 
not require a centrifugation step when working with non-adherent cells, which reduces 
manipulation errors (Tempone et al., 2011). Moreover, it has already been used as a 
viability indicator on antileishmanial drug screening assays towards axenic amastigotes 
as well as promastigotes (Spavieri et al., 2010a; Kulshrestha et al., 2013). 
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Over the last few years, the reporter gene technology has emerged as a valuable, 
sensitive and faster tool for quantifying the growth of intracellular forms. This technology 
is based on parasites transfected with a gene that has a measurable phenotype. Diverse 
reporter genes are mentioned in the literature including green or red fluorescent protein 
(Rocha et al., 2013), β-galactosidase (Okuno et al., 2003), β-lactamase (Mandal et al., 
2009) and firefly luciferase (Lang et al., 2005). Nevertheless, these assays are far from 
ideal. Not only they require sophisticated equipment, but also these genes may affect the 
parasite’s biology (Tempone et al., 2011). 
Regarding all difficulties inherent to drug screening against intracellular 
amastigotes, a rapid and sensitive screening method focusing on this parasite form would 
improve the efficacy of research of novel drugs against leishmaniasis. Although this 
hypothesis has been considered to be unreachable, the present work is a novel 
contribution towards this difficult goal.  
4. Thesis justification 
Intracellular amastigotes are pointed out as the ideal in vitro model for assessing 
the effect of antileishmanial drugs or compounds. These cells are obtained by infection 
of mammalian cell lines or peritoneal macrophages with both axenic promastigotes and 
amastigotes (Maia et al., 2007; Veermesch et al., 2009). Despite being labor-intensive, 
time-consuming, subjective, and dependent on the establishment of an amastigote-
macrophage system, the direct counting method still remains the gold standard 
methodology to evaluate the antileishmanial activity of natural products towards the 
clinically relevant stage of Leishmania parasites (Yazdanparast et al., 2014). The 
optimization process of this method depends on some critical steps, such as differentiation 
of the monocytic cellular line into adherent macrophages, infection with Leishmania 
promastigotes, treatment with the extracts or compounds and Giemsa staining of the 
slides. Because of its drawbacks, its use is usually limited to test compounds with verified 
antileishmanial activity in axenic promastigotes and/or amastigotes. However, as the use 
of these forms can result in missing potential hits, the attempt to use novel methodologies 
focusing on this parasite form is clearly needed. 
In this context, the parasite rescue method described by Jain et al. (2012) offers 
an interesting alternative to testing large numbers of extracts or compounds in a rapid, 
affordable, and sensitive manner, and may give more appropriate results. Nevertheless, 
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this methodology may require extensive optimization, in particular when experimental 
protocols for screening bioactive compounds need to be adapted to a novel target 
Leishmania species, as is the case for L. infantum. Still, the implementation of this method 
in laboratory routine is an undoubtedly a useful tool in the search for novel bioactive 
compounds. 
Considering that a majority of published studies have shown antileishmanial 
activity of marine extracts and having in mind the potential of marine organisms from the 
Iberian coast as sources of novel compounds with cytotoxicity to L. infantum has yet to 
be fully explored, a thesis on amastigotes-based assay optimization and screening for 
bioactive extracts against this parasite, clinically revelant to Portuguese human and canine 
populations, is needed. 
5. Objectives 
The main goal of this work is to contribute to the study of the potential of marine 
organisms and land plants living in habitats with marine influence as sources of 
compounds with antileishmanial activity. This will be attempted by optimizing screening 
methods, in particular those involving intracellular amastigotes. To accomplish this goal, 
several specific objectives were defined, namely: 1) optimization of the mammalian cell 
infection model; 2) optimization of two screening methods focusing on intracellular 
amastigotes of L. infantum, namely the direct counting upon Giemsa staining and and 
adaptation of the parasite rescue assay; 3) preparation of the macroalgae and halophyte 
extracts; 4) determination of the activity of macroalgae and halophyte extracts towards L. 
infantum promastigotes; 5) determination of the extracts cytotoxicity towards an in vitro 
mammalian model and selectivity indexes of the extracts; and 6) evaluation of the activity 
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This work was developed in the Marbiotech group of the Centre of Marine 
Sciences located at the Universidade do Algarve in collaboration with the Unidade de 
Leishmanioses of the Instituto de Higiene e Medicina Tropical (IHMT).  
The following procedures on this chapter were taken under aseptic conditions, in 
a laminar flow cabinet fitted with HEPA filters. 
1. Amastigote-macrophage model 
1.1. Parasites and cell cultures 
Human acute monocytic leukemia cell line (THP-1; ATCC® TIB-202™) and the 
human visceral Leishmania infantum strain MHOM/PT/88/IMT-151 were used in this 
study. Both cultures were kindly provided by the Unidade de Leishmanioses, Unidade de 
Parasitologia Médica, IHMT. 
Both cell line and parasite cultures were maintained in RPMI medium with L-
glutamine (Lonza) supplemented with 10% heat inactivated fetal bovine serum (FBS; 
Biochrom) and 1% penicillin (50 U mL-1)/streptomicin (50 μg mL-1; Pen/Strep; Lonza) 
at 36ºC ± 1ºC in 5% CO2 and 24 ± 1ºC, respectively. THP-1 flasks were incubated 
horizontally with ventilated cover and L. infantum flasks were incubated at an angle, to 
increase oxygenation. The medium was changed every 3 days. 
For infection assays, THP-1 and L. infantum promastigotes were maintained in 
RPMI without medium change for 4 and 5 days, respectively. Maintenance of cell and 
parasite lines is crucial to guarantee the availability of large quantities of cells but also to 
ensure that the L. infantum parasites were at the desired development phase for each 
assay. All infection assays were incubated at 36ºC ± 1ºC in 5% CO2. 
To avoid loss of virulence by the parasites as described elsewhere (Moreira et al., 
2012), experiments were carried out with parasites with less than 10 passages, after the 
first isolation from the murine model, whenever possible. 
1.2. Seeding and differentiation of mammalian cells 
As discussed in I-3.2, since THP-1 is a monocytic cellular line, differentiation of 
these cells into adherent macrophages is required for infection assays and has been 
addressed by treating cells with PMA (Daigneault et al., 2010).  
Chapter II – Material and Methods 
31 
 
To each assay, exponentially growing THP-1 cells (2,5 x 105 cells mL-1) were 
seeded in sterile 16-chamber, glass, microscopic culture slides (Millicell® EZ SLIDE). 
PMA (Sigma) was added to cell suspension at a final concentration of 25 ng mL-1 (Jain et 
al., 2012). To each well, 200 µL of the diluted cell suspension were dispensed and the 
chamber was incubated for 24 h, to allow the differentiation of THP-1 cells into adherent 
macrophages (De Muylder et al., 2011; Jain et al., 2012). 
1.3. In vitro infection of mammalian cells with L. infantum promastigotes 
1.3.1. Growth curve and relative percentage of metacyclic forms 
As mentioned before in I-1.1.1., metacyclic promastigotes are the infective forms 
of Leishmania spp. Therefore, for the determination of the day on which promastigotes 
should be added to the seeded adherent macrophages for infection, the growth dynamic 
and percentage of metacyclic forms in culture were assessed.  
L. infantum promastigotes cultures were maintained as described in II-1.1., and 
the parasites’ concentration was adjusted to 1,0 × 106 promastigotes mL-1. In a 12-well 
plate, 1 mL of culture was dispensed per well. To avoid cross-contamination, it was left 
one well between replicates. Cultures were followed for 9 days and the concentration of 
the parasite was determined by counting the number of viable promastigotes, in triplicate, 
using a Neubauer’s hemacytometer (Albuquerque, 2013). 
Metacyclic promastigotes were counted simultaneously, based on morphological 
parameters such as its slender body, elongated flagellum and high motility (Bates and 
Tetley, 1993), and its percentage was determined with reference to the total number of 
viable promastigotes counted. 
At day 3 and 5 of the growth curve, corresponding to logarithmic and stationary 
phases, respectively, L. infantum promastigotes were smeared on slides, stained by 
Giemsa (10% v/v; 10 min), observed in a light microscope (Motic BA310) and digital 
images were acquired for morphological analysis. 
1.3.2. Determination of the optimal parasite:cell ratio 
For the optimization of infection conditions, diluted suspensions of L. infantum 
promastigotes at the infective metacyclic stage were prepared with RPMI at 2% FBS, at 
5 different parasite:cell ratios, namely 1.25:1, 2.5:1, 5:1, 10:1 and 20:1.  
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THP-1 cells were seeded and differentiated in chamber slides, as described in II-
1.2. After differentiation, adherent macrophages were washed with 200 µL of serum-free 
RPMI, to remove the excess of PMA and 200 µL of the each diluted parasite suspension 
were added. The chamber slide was then incubated for 24 h. Non-infected control cells 
were included as negative control (De Muylder et al., 2011; Jain et al., 2012). 
After 24 h, wells were washed five times with 200 µL of serum-free RPMI 
medium, to ensure the removal of non-internalized promastigotes. The plastic chamber 
was detached from the slide, which was left at the laminar flow cabinet for drying. When 
dried, the slide was immersed in MeOH for 30 s, washed with distilled water (H2Od) and 
left to dry, before being stained by Giemsa (10% v/v in H2Od, 10 min; Sigma).  
The slides were observed by light microscopy under oil at a x1000 magnification 
and the percentage of infected cells (i.e. number of infected macrophages per 100 
macrophages counted) and the intensity of infection (i.e. number of amastigotes per 
infected cells) were determined (Maia et al., 2007). 
1.3.3. Determination of the optimal infection period 
Since some reports are available in the literature that refer that lower times of 
incubation are sufficient in order to obtain good infection rates (Dasgupta et al., 2003; 
Maia et al., 2007; Jain et al., 2012), three different times were tested: 4, 16 and 24 h. 
Therefore, THP-1 cells were seeded and differentiated in chamber slides as described in 
II-1.2. and infected as referred to in  II-1.3.2, using the optimal parasite:cell ratio. The 
chamber slides were incubated for 4, 16 and 24 h. Afterwards, slides were dried, stained 
with Giemsa and the percentage of infected cells and the intensity of infection were 
determined as described in II-1.3.2. 
2. Intracellular susceptibility assays 
One of the aims of this work was the optimization of two methods focusing on 
intracellular amastigotes: the direct counting method after Giemsa staining and an 
adaptation of the parasite rescue assay described by Jain et al. (2012). 
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2.1. Direct counting method 
 After establishment of the amastigote-macrophage model, to ensure that the 
method was prepared to test the effect of extracts, the effect of the standard drug AmB 
was evaluated, as positive control. 
2.1.1. Evaluation of the effect of the standard drug, AmB 
The THP-1 cells were seeded and differentiated as described in II-1.2. and 
infected for 24h at a ratio of 10:1 as described in II-1.3.2 (Figure 4). Six diluted 
suspensions of AmB  were prepared, ranging from 4 to 0.0625 µg mL-1, obtained from 
serial dilutions (1:2) with RPMI medium at 2% FBS. Non-treated cells were included as 
negative control. After 5 washes, 200 µL of each suspension was added to each well and 
the chamber was incubated for 48 h. When the treatment period ended, the chamber was 
washed three times with serum-free RPMI, detached and stained with Giemsa.  
The percentage of infected cells and the intensity of infection were determined as 




Figure 4 Schematic representation of the steps involved in the direct counting method 
(Original from Oliveira, M.). 
2.2. Parasite rescue assay 
Because of the drawbacks of the direct counting method, it was proposed to adapt 
the parasite rescue method developed by Jain et al. (2012), discussed earlier in I-3.2., by 
adding the resazurin immediately after lysis of infected cells and measure the viability of 
released amastigotes, eliminating the 48 h step for the transformation of the parasites.   
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2.2.1. Optimization of the controlled cell lysis 
The procedure of this methodology is similar to the direct counting method till the 
treatment of the infected cells. Afterwards, a critical step is the controlled cell lysis using 
SDS solution and mechanic agitation of the plate (Figure 5). 
 
Figure 5 Schematic representation of the purposed adaptation of the parasite rescue assay 
(Original from Oliveira, M.). 
To assess the optimal time for agitation of the plate after adding the SDS solution, 
i.e. time of lysis, three different times were tested, respectively 15, 30 and 60 s. 
THP-1 cells were seeded and differentiated as described in II-1.2., and infected as 
described in II-1.3., in 96-well black (NUNC) and clear (Orange Scientific) plates. Since 
the use of clear plates for fluorimetric measurements are described by Jain et al. (2012), 
experiments were carried out on both clear and black plates to ensure that results were 
not significantly different in both plate types. 
Control wells of non-infected cells were included in each experiment. Medium 
with SDS and without cells was used for background correction. Simultaneously, a 96-
well clear plate was also included, to enable the observation of all the experiment steps 
under the inverted microscope. 
After incubation period, the wells were washed 5 times with serum-free RPMI 
medium and 200 µL of RPMI at 2% FBS were added to each well. Plates were incubated 
for 48 h, to simulate the treatment with standard drugs or extracts. A solution of SDS 
(0.05 % v/v in serum-free RPMI) was prepared and 20 µL added to each well. After 
addition of the SDS solution, the plate was agitated for 15, 30 and 60 s, respectively. To 
inactivate the SDS, after the agitation time, 180 µL of RPMI at 10% FBS were added. 
To each well, 20 µL of resazurin (250 µg mL-1) were added and the plate was 
incubated for 24 h. The fluorescence was measured in a microplate flourimeter (Biotek 
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Synergy 4) at 550 and 590 nm as excitation and emission wavelengths, respectively. 
Results were expressed as percentage of viable cells, by comparison to the negative 
control cells, i.e., cells which were not subjected to lysis. 
After lysis under the different times, both non-infected and infected cells were 
observed in an inverted microscope and images were acquired with a Canon EOS 500D 
camera to support the results obtained by fluorimetric measurements.  
2.2.2. Evaluation of the effect of different parasite:cell ratio 
To address if the method was able to discriminate different concentrations of 
released amastigotes, different parasite:cell ratios were applied in order to obtain 
increasing infection rates. Both the direct counting and parasite rescue methods were 
performed simultaneously. 
Briefly, 16-well glass chamber slides were processed as described in II-1.3.2., and 
96-well black plates were processed as explained in II-2.2.1., using different ratios and 
30 s as the optimal lysis time.  
A negative control of non-infected cells was included. Medium with SDS and 
without cells was used for background correction. RPMI medium at 10% with 20 µL of 
resazurin (250 µg mL-1) were autoclaved for 15 min at 121ºC and used as positive control, 
resulting in a 100% reduced form of resazurin. Results were expressed as percentage of 
viability in comparison to non-infected cells, for 96-well plates. For 16-well glass 
chamber slides, results were expressed as percentage of infected cells and intensity of 
infection, as described previously in II-1.3.2. 
2.2.3. Evaluation of the effect of the standard drug, Amphotericin B 
For validation purposes, the effect of the standard drug AmB, was simultaneously 
evaluated using the parasite rescue method and the direct counting method. Briefly, 16-
well glass chamber slides were processed as described in II-2.1.1. and 96-well black 
plates were processed as referred in II-2.2.1. using 30 s as the optimal lysis time.  
A negative control of non-treated infected cells and a positive control for resazurin 
were included. The viability of amastigotes were obtained by comparison with the 
negative control wells, i.e. non-treated cells and the IC50 values (µg mL
-1) were 
determined. 
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3. Preparation of the extracts for antileishmanial screening 
The macroalgae and halophyte material used in this study were provided by works 
in course at the MarBiotech Group.  
3.1. Preparation of macroalgae and halophyte extracts 
Concerning the macroalgae, all the samples belong to the Cystoseira genera, and 
were collected between July 2012 and March 2013 in different locations of the Iberian 
Peninsula (Table 4). Each sample was extracted with three solvents of increasing polarity, 
namely hexane (HEX), dichloromethane (DCM) and methanol, resulting in a total of 23 
extracts. Only the C. barbata and the C. nodicaulis extracts were prepared in this work. 
Table 4 Collection sites of the Cystoseira species used in this study 
  
 
Dried biomass (4 g) was powdered and mixed with 40 mL of HEX, in triplicate. 
The rupture of algal cell walls was achieved with an IKA Ultra-Turrax disperser for 1 
min. Samples were then homogenized (VWR VV3) and centrifuged 10 min at 5000 × g, 
at room temperature (RT). This procedure was repeated three times and then extracts were 
filtered with Whatman nº4 filter and combined. The residue was then sequentially 
extracted with dichloromethane and then methanol, filtered and concentrated under 
reduced vacuum pressure at 40ºC. Extracts were dissolved in DMSO (Merck) at a 
concentration of 50 mg mL-1 and stored at 4ºC.  
Halophyte samples were collected in June 2013, in Ria Formosa, Portugal. A total 
of 26 species were included in this study for antileishmanial screening (Table 5). The 
aerial parts of each species were prepared and extracted with two solvents by stirring for 
Species Collection site 
Cystoseira baccata Areosa, Portugal 
Cystoseira barbata Cadiz Bay, Spain 
Cystoseira humilis Almograve, Portugal 
Cystoseira nodicaulis Santa Mariña, Spain 
Cystoseira tamariscifolia Areosa, Portugal 
Cystoseira usneoides Olhos de Água, Portugal 
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4 hours, namely acetone and dichloromethane, resulting in a total of 52 extracts. Extracts 
were filtered, concentrated under reduced vacuum pressure, ressuspended in DMSO at a 
final concentration of 25 mg mL-1 and stored at 4ºC for use in the bioactivity assays.  
Table 5 Halophyte species used in this study. 
Species 
Arthrocnemum macrostachyum Panicum repens 
Aster tripolium Pistacia lentiscus 
Calystegia soldanela Puccinelia sp. 
Centaurium erythraea Salicornia fragilis 
Cladium mariscus Salicornia ramosissima 
Frankenia laevis Salicornia perennis alpine 
Frankenia pulverulenta Salicornia perennis perennis 
Halopeplis amplexicaulis Spartina versicolor 
Inula crithmoides Spergularia rubra 
Lactuca sp. Sporobolus sp 
Limoniastrum monopetalum Salsola sp. 
Lythrum salicaria Salsola vermiculata 
Mesembrianthemum crystallinum Typha dominguensis 
 
In Soxhlet extraction, the dried biomass of C. baccata and C. barbata was taken 
into cellulose thimble in a ratio of biomass to solvent (1:6 w/v), placed in Soxhlet 
apparatus, refluxed for 8 hr until free of solvent colour, and it was using 
hexane:dichloromethane (HEX:DCM; 1:1). After extraction, solvent was removed using 
rotary evaporator under reduced vacuum pressure at 40ºC,, dissolved in DMSO at the 
concentration of 50 mg mL-1 and stored at 4°C. 
4. Antileishmanial and cytotoxic activity of the extracts 
4.1. Parasite and cell cultures 
THP-1 cell line and Leishmania infantum strain MHOM/PT/88/IMT-151 were 
used in this study. Both cell and parasite cultures were maintained in RPMI medium as 
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described in II-1.1.  
For viability assays, THP-1 and L. infantum promastigotes were maintained in 
RPMI medium for 3 days.  
4.2. Evaluation of the effect of the extracts on axenic promastigotes  
4.2.1. Determination of the promastigotes viability and 50% inhibitory 
concentration 
Parasites viability was assessed on promastigotes forms of L. infantum by MTT 
assay. Briefly, the conversion of the tetrazolium salt MTT in the mitochondria of viable 
cells into purple formazan crystals, allows the quantification of viable cells, by 
spectrophotometric measurements (Van Meerloo et al., 2011). 
The antileishmanial activity of a total of 52 extracts of halophytes and 23 extracts 
of the brown macroalgae was evaluated. In sterile clear 96-well plates, log phase 
promastigotes (1,0 x 107 promastigotes mL-1) were incubated with extracts at 125 μg mL-
1. Macroalgae and halophyte extracts were incubated for 48 and 72 h, respectively. 
Negative control cells were treated with DMSO at the highest concentration used in test 
wells (0,5 % v/v) and AmB, miltefosine and pentamidine were used as positive controls, 
at their previously determined IC50 values. 
After incubation, 20 µL of MTT reagent (5 mg mL-1 in phosphate-buffered saline, 
PBS) were dispensed in each well and the plate was then incubated for 2 h at 36 ± 1 ºC at 
5% CO2. Since the parasites are in suspension, the plate was centrifuged for 15 min at 
1479 × g, at 4 ºC and the supernatant was carefully removed. In order to dissolve the 
formazan crystals, 150 μL of DMSO were added per well. The absorbance was read in a 
microplate reader (Biotek Sinergy 4) at an emission wavelength of 590 nm, as described 
elsewhere (Rodrigues et al., 2014).  
Extracts that inhibit the viability of parasites in more than 50 % at 125 µg mL-1, 
were then tested, also by MTT assay, at seven different concentrations, ranging from 1.98 
to 125 μg mL-1 and the IC50 values were determined. 
4.2.2. Microscopy analysis of the promastigotes morphology 
For microscopic analysis, parasites were incubated with the selected extracts for 
48h, at 24 ± 1ºC, as described in II-4.2.1. After the end of the incubation period, 
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supernatants were centrifugated for 15 min at 1479 x g, at 4ºC, and the supernatant further 
discarded. The pellet was ressuspended in 20 µL of RPMI supplemented with 50% FBS 
and smeared on slides. After being dried and fixed with MeOH for 30 s, air-dried smears 
were stained with Giemsa (10% v/v; 10 min). After rinsed with H2Od and air-dried at RT, 
slides were directly covered with a slide and processed for microscopy analysis. 
Microscopic bright field images were acquired using a Zeiss AXIOMAGER Z2 
microscope, equipped with a coolSNApHQ2 camera and AxioVision software version 
4.8 (Carl Zeiss MicroImaging GmbH, Göttingen, Germany) at the light microscopy 
facility of the Departmento de Medicina e Ciências Biomédicas of the Universidade do 
Algarve. 
4.3. Evaluation of the effect of the extracts on mammalian cells 
4.3.1. Determination of the THP-1 viability and IC50 concentration  
Cytotoxicity was assessed on THP-1 cells by MTT colorimetric assay. Sterile 96-
well plates were seeded with exponentially growing THP-1 cells at 1,0 x 105 cells mL-1. 
PMA was added to the cell suspension at a final concentration of 25 ng mL-1 and 100 µL 
of the suspension were dispensed per well and incubated for 24 h to allow cells 
differentiation into adherent macrophages. The medium was then replaced by RPMI 
containing the macroalgae and halophytes extracts at 125 µg mL-1 and plates were 
incubated for 48 and 72 h, respectively. Control cells were treated with DMSO at the 
highest concentration used in test wells (0,5 % v/v) and cell viability was determined by 
the MTT assay, as described in II-4.2.1.  
Extracts inhibiting the viability of THP-1 cells in more than 50 % at 125 µg mL-
1, being also active against L. infantum promastigotes, were then tested by the MTT assay, 
at seven different concentrations, ranging from 1.98 to 125 μg mL-1 and the IC50 values 
were determined.  
4.3.2. Determination of the selectivity index 
To evaluate the effectiveness of an extract against L. infantum, its selectivity index (SI) 
was calculated as follows: 
SI = IC50 (THP-1)/ IC50 (L. infantum) 
Chapter II – Material and Methods 
40 
 
where the numerator and the denominator represent the concentration of a extract required 
for 50% in vitro inhibition of THP-1 macrophages and the concentration of the same 
extract needed for 50% in vitro inhibition of L. infantum parasites, respectively. The 
selectivity index is a ratio that reflects the effectiveness of an extract, as discussed in I-3.  
4.4. Evaluation of the effect of the extracts on the amastigote-macrophage 
model 
The effect of the HEX:DCM extracts of C. baccata and C. barbata, obtained by 
hot Soxhlet-based extraction method, were evaluated towards L. infantum intracellular 
amastigotes. The citotoxicity of the extracts was previously evaluated as described in II-
4.3.1. 
The THP-1 cells were seeded and differentiated as described in II-1.2. and 
infected for 24h at a ratio of 10:1 as described in II-1.3.2. Six diluted suspensions of the 
extracts were prepared, ranging from 3.9 to 125µg mL-1, obtained from serial dilutions 
(1:2) with RPMI medium at 2% FBS. Control cells were treated with DMSO at the highest 
concentration used in test wells (0.5 % v/v) were used as negative control. After 5 washes, 
200 µL of each suspension was added to each well and the chamber-slide was incubated 
at 36ºC ± 1ºC in 5% CO2 for 48 h. When the treatment period ended, the chamber was 
washed three times with serum-free RPMI, detached and stained with Giemsa. The 
percentage of infected cells and the intensity of infection were determined as described 
in II-1.3.2. The IC50 values were determined. 
5. Statistical analysis and IC50 determination 
The statistical analysis was performed using the Statistical Package for Social 
Sciences (SPSS) software version 20.0 for Windows. Analysis of variance (ANOVA) 
was used to assess differences between groups. When the null hyphotesis was accepted, 
multiple comparisons were performed to identify the statistically different groups at a 
significance level of 5% (p < 0.05), using the Tukey’s and Dunnet’s tests. 
The IC50 values were calculated by sigmoidal fitting of the data in the GraphPad 
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1. Amastigote-macrophage model 
1.1. Growth curve and relative percentage of metacyclic forms 
To assess the growth dynamics of L. infantum promastigotes maintained in RPMI-
1640 supplemented medium, daily counts of viable parasites were made for 9 days, 
without medium change. L. infantum presented low parasite densities, not exceeding 2 x 
107 promastigotes mL-1 (Figure 6).  
Metacyclogenesis occurs within the phlebotomine sand fly, in which parasites 
differentiate into infective promastigotes, named metacyclics. During this process, the 
parasite suffers morphological, structural and biochemical changes and also variations in 
gene expression (Saraiva et al., 1995; 2005). These alterations occur in axenic cultures, 
where a fraction of promastigotes from a logarithmic non-infective stage, which resemble 
procyclic promastigotes, are able to differentiate into stationary infective stage 
promastigotes, similar to their phlebotomine sand fly counterparts (Saraiva et al., 1995; 
2005).  
Giemsa smears were prepared and observed at day 3 and 5, representative of 
logarithmic phase and stationary phase, respectively (Figure 7). In general, at day 3 
promastigotes presented rounded shape and short flagella. However, concerning the width 
of the cell body, mixed morphology was observed. The variability in the length of the cell 
body may be due to the fact that promastigotes are already in early stationary phase. The 
observed forms appear to be a mixture of procyclic and nectomonads, the latter being 
accepted as the second morphological stage in the midgut of the sand fly, more elongated 
than procyclic ones, as referred in I-1.1 (Kamhawi, 2006).  
At day 5, promastigotes were highly motile and a high percentage of cells 
presented slender cell bodies in a characteristic needle shape with long flagella (flagellum 
> body length). These forms appeared to be leptomonads, the precursor forms of 
metacyclic promastigotes, which rapidly differentiate into the latter (Kamhawi, 2006; 
Kbaier-Hachemi et al., 2012). In fact, these observations were also carried out by 
Santarém et al. (2014) with L. infantum promastigotes cultivated in RPMI medium. 
 
 





Figure 6 Growth dynamics of L. infantum IMT 151 axenic promastigotes maintained in 
RPMI. Light grey line represents the growth curve (promastigotes mL-1); dark grey bars 
represent the percentage of metacyclic forms observed at each day. Both represent the 
mean ± SEM (standard error of the mean) of two independent experiments with three 
replicates each. a, no statistically differences between day 5 and 6, concerning % of 
metacyclic forms (p > 0.05; Tukey’s test).  
 
Figure 7 Predominant morphology of L. infantum axenic promastigotes cultured in RPMI 
medium. After 3 and 5 days of culture, promastigotes were smeared on slides and 
observed under a light microscopy. Bright field images, scale bar corresponds to 10 µm. 
Chapter III – Results and Discussion 
44 
 
The distinction of metacyclic from procyclic parasites morphology is 
controversial. Some authors used to defend that there was no obvious morphological 
changes during metacyclogenesis (Da Silva and Sacks, 1987). However, recent studies 
on the purification of metacyclic promastigotes rely on clear morphological differences 
between the former and procyclic promastigotes (Spath and Beverly, 2001; Saraiva et al., 
2005).  
Morphological differences between parasites at the logarithmic and stationary 
phases were also observed in L. infantum promastigotes cultured in different mediums 
(Santarém et al., 2014). Thus, metacyclic promastigotes are generally accepted as small 
body cells with an elongated free flagellum, which is equal or greater than the body length 
and highly motile (Kamhawi, 2006; Bates, 2007).  
Because of the subjectivity of optical microscopic counts, which can sub- or 
underestimate the number of metacyclic forms, other methods have been used by different 
authors in order to assess the metacyclogenesis process. For example, a clear 
overexpression of META-1 and SHERP genes at day 5, which are described as being 
express during metacyclogenesis, was observed for L. infantum promastigotes cultured in 
RPMI medium, supporting the results presented before (Moreira et al., 2012; Santarém et 
al., 2014). Furthermore, a method using negative peanut agglutinin (PNA) selection was 
shown to be as efficient to differentiate non-infectious (PNA+) and infectious forms 
(PNA-) of L. infantum promastigotes. The percentage of PNA- forms were found at day 4 
of culture, reaching a maximum of 80 %, when visceral strains were used (Kbaier-
Hachemi et al., 2012). 
Although the percentage of metacyclics may be overestimated in this study in 
comparison with other published works (Albuquerque et al., 2013), based on our results 
and those of others published on L. infantum (Maia et al., 2007; Moreira et al., 2012), a 5 
day old culture of promastigotes was choosen for in vitro infection of macrophages, since 
no significant differences were observed between day 5 and 6 (p > 0.05). In future work, 
the purification of metacyclics might reduce the risk of infectivity variability, as in vitro 
infection of macrophages is dependent on the metacyclogenesis level.  
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1.2. Determination of the optimal parasite:cell ratio and infection period 
To assess which parasite per macrophage ratio should be used for infection assays, 
five different ratios from 1.25:1 to 20:1 were applied. Two parameters were determined, 
namely the percentage of infected cells and the intensity of infection (Maia et al., 2007; 
Figures 8 and 9). 
At 10:1 and 20:1, almost all macrophages became infected and the results 
obtained enable the determination of a dose-response curve (Figure 8). Statistically 
significant differences were observed between 5:1 and 10:1. However, no significant 
differences were observed between 10:1 and 20:1 (p > 0,05; Tukey’s test) for the 
percentage of infected cells. As 50-70 % is thought as an adequate percentage of infected 
cells by some authors (Inocêncio da Luz et al., 2009), only 10:1 and 20:1 ratios were 
considered for in vitro infection.  
Concerning the intensity of infection, no statistically significant differences were 
observed between 10:1 and 20:1 ratios (p > 0.05, Tukey’s test; Figure 9). The ratio 10:1 
was thus established as optimal for in vitro infection assays, since 20:1 did not enhance 
the results significantly, hampered the microscopic countings and high densities of 
promastigotes must be used for each assay. Several different ratios have been described 
for in vitro infections with Leishmania spp., the ratio chosen being within the range of 
those most commonly used in other studies (Inocêncio da Luz et al., 2009; Seifert et al., 
2010; Christodoulou et al., 2011; Jain et al., 2012). 
 
 




Figure 8 Percentage of infected cells obtained for different parasite:cell ratios. Bars 
represent the mean ± SEM, obtained from two independent experiments with two 




Figure 9 Intensity of infection obtained for each parasite:cell ratio applied. Bars represent 
the mean ± SEM, obtained from two independent experiments with two replicates each. 
Bars with different letters are significantly different (p < 0.05; Tukey’s test). 
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It is described that short incubation periods were sufficient to obtain good 
infection rates (Seifert et al., 2010; Jain et al., 2012). In this context, three different 
incubation periods were tested, namely 4, 16 and 24 h (Figure 10). After 4 and 16h, no 
significantly differences were observed, and the percentage of infected cells reached a 
maximum of about 37%. After 24 h, about 70% of the cells became infected, as presented 
before (Figure 11). 
 
Figure 10 Percentage of infected cells after different incubation periods with 5 day old 
promastigote culture. Bars represent the mean ± SEM, obtained from two independent 
experiments with two replicates each. Bars with different letters are significantly different 
(p < 0.05; Tukey’s test). 




Figure 11 THP-1 derived macrophages infected with a 5 day old culture of metacyclic 
promastigotes of L. infantum, at a 10:1 infection ratio, for an infection period of 24 h 
(Original from Oliveira, M.). Scale bar corresponds to 10 µm. 
 
Having in mind the results presented so far, the optimal conditions for the 
infection with L. infantum promastigotes were defined. Therefore, for infection assays, a 
5 day old culture of L. infantum promastigotes was chosen for further assays of this study 
at a parasite:cell infection rate of 10:1 and subsequent incubation for 24 h in the presence 
of THP-1-derived macrophages. 
2. Intracellular susceptibility assays 
2.1. Direct counting method  
AmB is a second-line drug widely used to treat leishmaniasis. It interacts with the 
ergosterol present in the parasite’s membrane, leading to membrane disruption (Balaña-
Fouce et al., 1998).  
When comparing the IC50 values obtained for the promastigotes (IC50, 0.6 ± 0.0 
µg mL-1) and the intracellular amastigotes (IC50, 0.1 ± 0.0 µg mL
-1), it is clear that the 
second are more sensitive to the drug (Table 6). AmB didn’t demonstrated cytotoxicity 
towards THP-1 cell line at the maximum concentration tested of 125 µg mL-1. 
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Table 6 Antileishmanial activity against the promastigote and intracellular amastigote 
stages, cytotoxicity towards THP-1 cells and selectivity indexes, obtained for the standard 





IC50 values          
(µg mL-1) 
0.6 ± 0.0 0.1 ± 0.0 >125 





Values represent the mean ± SEM of at least three independent experiments performed in duplicate. 
 
The different IC50 values obtained are reflected in the selectivity index, which increased 
five times for intracellular amastigotes. This fact is also referred by Vermeersch et al. 
(2009) who observed a higher specificity of AmB for the amastigote than for the 
promastigote stage of L. donovani. Moreover, when the susceptibility of L. mexicana 
promastigotes and intracellular amastigotes to six different antileishmanial drugs was 
compared, four of them presented different IC50 values for the two parasite stages 
(Callahan et al., 1997). Finally, this parasite stage-dependent specificity may be related 
to the mechanisms of action of the drugs or compounds, which reinforces the statement 
that promastigotes may not represent the ideal in vitro model for drug screening (Sereno 
et al., 2007).  
2.2. Parasite rescue assay 
2.2.1. Optimization of controlled cell lysis 
After lysis with 0,05% SDS for 15, 30 and 60 s, a microscopic evaluation of the 
non-infected and infected wells was carried out in order to decide the ideal time of lysis 
(Figure 12). The optimal time should allow the lysis of the higher number of 
macrophages, slightly affecting the released amastigotes. Fifteen seconds were 
insufficient to achieve lysis of both non-infected as infected cells, once that a large 
number of macrophages was observed per field and consequently few intracellular 
amastigotes were released. After 30 s, even though some remaining macrophages were 
observed, the number of released amastigotes had increased considerably.  




Figure 12  Microscopic evaluation of non-infected and infected macrophages at different 
times of lysis. A duration of 30 s was sufficient for quasi-complete lysis of macrophages 
with liberation of amastigotes (arrows). Non-infected macrophages lysed for 15 (A), 30 
(C) and 60 s (E); infected macrophages lysed for 15 (B), 30 (D) and 60 s (F) (x 400). 
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After 60 s, macrophages or released amastigote forms were scarce in both infected 
and non-infected wells. These observations suggest that 60 s seems to be excessive, the 
SDS solution apparently affecting both cell lines. Taken together, the results of the 
microscopic evaluation allowed us to determine 30 s as the optimal lysis duration. 
The measurement of the viability of L. infantum released amastigotes was 
assessed immediately after the lysis of infected cells, in both clear and black plates. The 
fluorescence signal of non-infected wells was also measured. Experiments performed in 
clear plates, after lysis of both infected and non-infected cells were not in accordance with 
the microscopic observations (Figure 13). In fact, results were very similar between all 
times tested and only a significant decrease in viability was observed after 60 s of plate 
agitation upon addition of SDS. Oddly, at 15 s, infected cells also presented a significant 
(p < 0.05) decrease. 
 
 
Figure 13 Viability of infected and non-infected cells in 96-well clear plates, non-lysed 
and lysed after 15, 30 and 60 s of plate agitation in the presence of SDS. Bars represent 
the mean ± SEM, obtained from two independent experiment with at least three replicates 
each. Statistically significant differences (p < 0.05; Dunnnet’s test) in viability between 
control (i.e. non-lysed) and lysed cells at different times are marked with an *. 
 




The disparity of these results can be attributed to the fact that clear plates are not 
recommended for fluorimetric measurements, although some authors use them in 
fluorescence based assays (Jain et al., 2012). Black plates present lower background, 
reduce well-to-well interference and minimize light scattering (Shekarchi et al., 1985; 
Corning Life Sciences, 2007). Therefore, the use of clear plates for this assay was 
abandoned. 
Fluorescence measurements using black plates were somewhat different from 
those obtained for clear plates (Figure 14). Cells not subjected to lysis presented similar 
high fluorescence signals, with a slight increase in the arbitrary fluorescence units (AFU) 
in infected wells in comparison to non-infected (data not shown). Considering the minor 
difference between non-infected and infected cells and the fact that macrophages also 
metabolize resazurin, the need to lyse the cells was undoubtedly relevant to assess the 
effect of a drug on the intracellular parasites.  
 
Figure 14 Viability of infected and non-infected cells in 96-well black plates, before and 
after 15, 30 and 60 s of plate agitation in the presence of SDS. Bars represent the mean ± 
SEM, obtained from two independent experiment with at least three replicates each. 
Statistically significant differences (p < 0.05; Dunnnet’s test) in viability between control 
(i.e. non-lysed) and lysed cells at different times are marked with an *. 
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Although a small decrease in viability is evident after 15 s of agitation, a small 
positive difference between the viability for infected and non-infected wells can be 
verified. As observed in the microscopy images, few intracellular amastigotes were 
released and the majority of macrophages remained intact and metabolized resazurin.  
After 30 s, the viability of infected cells (89.4 ± 2.6 %) remained unaltered when 
compared to that observed after 15 s (92.6 ± 2.6 %), while the AFU of the non-infected 
cells decreased significantly (48.3 ± 8.2%). This SDS agitation time induced the lysis of 
macrophages without affecting the viable amastigotes, confirming the observations at the 
inverted microscope. At 60 s an evident decrease in viability of both infected (65.3 ± 
6.6%) and non-infected (44.8 ± 4.3%) cells was observed, suggesting that such exposure 
to SDS was excessive, resulting in lysis of both macrophages and released amastigotes. 
Although a viability of 44.8 % after 60 s of agitation was measured, few macrophages 
were observed in the digital images acquired. This is in agreement with the  literature 
describing resazurin as being highly sensitive, since it can detect as low as 80-200 cells 
per well (O’Brien et al., 2000; Hamid et al., 2004; Borra et al., 2009).  
Thus, for parasite rescue assay, 30 s were chosen as the optimal duration of SDS-
induced cell lysis, because it promotes the lysis of almost all macrophages without 
significantly affecting the viability of the released amastigotes. Such a result is in 
accordance with previous studies (Jain et al., 2012). As the percentage of remaining 
macrophages after lysis was considered to be similar in all wells, only the infected wells 
were measured in further experiments.  
2.2.2. Fluorimetric quantification of resofurin: pitfalls and challenges 
The capability of the parasite rescue assay to discriminate different concentrations 
of released amastigotes was assessed by using 5 different parasite:cell ratios (Figure 15). 
Results were compared with the direct counting method, the classical approach optimized 
earlier (Figure 16).  
 




Figure 15 Viability obtained for infected cells with different ratios in 96-well black plates 
by means of the parasite rescue assay. Bars represent the mean ± SEM of two independent 
experiment with at least three replicates. Bars with different letters are significantly 
different (p < 0.05; Tukey HSD). 
 
Figure 16 Percentage of infected cells obtained with different parasite:cell ratios in 16-
well chamber slides by means of the direct counting method. Bars represent the mean ± 
SEM of two independent experiment with two replicates. Bars with different letters are 
significantly different (p < 0.05; Tukey’s test). 
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Interestingly, the results obtained by the parasite rescue assay presented an 
inverted pattern in comparison to the results obtained by the direct counting method. 
As mentioned in I-3.3., resazurin is metabolized by living cells into the fluorescent 
product, resorufin. As a result, the viability of cells is directly proportional to the 
fluorescence produced. In this context, it would be expected that higher parasite:cell ratios 
applied should result in higher AFU due to increased cell counts, as observed in the direct 
counting method. However, the lower ratio presented the highest fluorescence values 
associated with higher viability. When AmB was tested as positive control, the same 
inverted pattern was detected, in which viability apparently decreased when lower 
concentrations of the drug were tested (Figure 17). 
 
 
Figure 17 Effect of the standard drug AmB against intracellular amastigotes by means of 
the parasite rescue assay, with a parasite:cell ratio of 10:1. Bars represent the mean ± 
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Resazurin is a blue non-fluorescent dye that has been widely used to assess the 
growth or inhibition of different types of cells. Despite its advantages, certain precautions 
should be considered during the optimization of resazurin-based methods, namely the 
cross reactivity of compounds (O’Brien et al., 2000; Stoddart, 2011). Thus, AmB was 
tested without cells to guarantee that it was not chemically reacting with resazurin 
producing a fluorescent product. Still, in experiments carried out with the different ratios, 
besides cells and parasites, no compound was added that would produce fluorescence 
when exposed to resazurin, and the inverted pattern persisted. 
Moreover, the reduction rate of resazurin depends on the cellular line used which 
will further influence the resazurin concentration and incubation time optimization 
(O’Brien et al., 2000). This second step relies on the fact that the fluorescent product of 
resazurin, namely resorufin, can be further reduced into a colourless, non-fluorescent 
compound called dihydroresorufin (Figure 18; Rampersad, 2012).  
 
 
Figure 18 Metabolism of resazurin in mammalian cells (Fukushima et al., 2003). 
 
This phenomena is known to occur in the presence of high cell densities or 
excessive incubation times (Rampersad, 2012). In this context, aberrant results may 
occur, as the living cells produce weak fluorescence signals due to the conversion into 
the non-fluorescent compound, and the dying cells produce high fluorescence because 
they can no longer further reduce resorufin (O’Brien et al., 2000). In fact, the 
characteristic metabolism of resorufin was already described as a useful tool to access the 
cytotoxicity on mammalian cells by long-term incubation with resazurin, giving more 
reliable results concerning cell death rather than being dependent on the number of viable 
cells (McMillian et al., 2002). 
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Having in mind the resorufin metabolism, it appears that this reduction probably 
influenced the results obtained during this study, assuming that at lower concentrations 
of AmB few amastigotes are present and vice-versa. Thus, the percentage of viability 
achieved may be the percentage of cellular death, due to excessive resazurin and resorufin 
reduction. Nonetheless, concerning the parasite:cell ratios experiment, it was expected 
that the higher the ratio used, increased infection rates were obtained, resulting in more 
released amastigotes, and thus increased fluorescence. 
During this study, plates were incubated for 24 h. Most probably, if the incubation 
time was extended for additional 48 h, more consistent results would be obtained 
regarding cell death. In contrast, and more accurately, lower incubation times would give 
results comparable to those obtained by other viability assays, since the resorufin would 
not be reduced and the fluorescence signal would be associated to cell viability 
(McMillian et al., 2002). 
Besides the incubation time, another factor relevant to this topic is the resazurin 
concentration used. Preliminary tests using resazurin in the MarBiotech group were 
carried out at 2.5 µg per well, because it is the most commonly used concentration for 
viability assays using promastigotes of Leishmania (Spavieri et al., 2010a). However, at 
this concentration, no significant fluorescence signals were obtained. Hence, for this 
study, the concentration of resazurin was increased to 6.25 µg per well with further 
incubation for 24 h , which was also previously described for promastigotes (Kulshrestha 
et al., 2013). 
Nevertheless, the parasite forms metabolizing resazurin used in this study were 
the released amastigotes, which are comparable to axenic amastigotes. Resazurin has also 
been used to assess the viability of axenic amastigotes in drug screening assays (Spavieri 
et al., 2010a). 
Curiously, the axenic amastigotes were found to attain the fluorescence peak 
faster than promastigotes, with further decrease in fluorescence at elevated parasite 
densities and excessive incubation times (Shimony and Jaffe, 2008). These differences 
observed between the reduction rates of promastigotes and amastigotes have been 
suggested to be caused by different incubation temperatures and atmospheres, since the 
latter are maintained at 36ºC with 5% CO2 and the former at 25ºC (Mikus and Steverding, 
2000).  
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In fact, a resazurin-based method applied to evaluating cell growth and inhibition 
of Leishmania promastigotes yielded more consistent results when plates were incubated 
in 5% CO2 atmosphere or reduced air availability, allowing the efficient reduction of 
resazurin (O’Brien et al., 2000; Corral et al., 2013). 
As discussed before, the remaining macrophages in the wells may also have 
contributed to the aberrant results shown in figures 15-17, by enhancing fluorescence 
quenching through metabolization of the resazurin and, consequently, the resorufin 
compound. Again, this could have been avoided if different conditions were applied. 
Therefore, the number of remaining cells results in a background signal in all wells. 
In summary, and having in mind all the results discussed in this section, the 
resazurin concentration and incubation time used in this study was shown to be inadequate 
for the assessment of the viability of the released amastigotes. In future experiments, both 
lower incubation times and resazurin concentrations should be tested to completely 
optimize the assay. 
Although resazurin-based methods are undoubtedly simple, fast, less expensive 
and pointed out as giving accurate results, the optimization process may be long and 
difficult, even more so when two different types of cells are used, in this case the 
mammalian cellular line THP-1 and L. infantum parasites (O’Brien et al., 2000). 
As argued above, the parasite rescue assay relies on the success of several critical 
steps such as the differentiation of cells into adherent macrophages, infection with L. 
infantum promastigotes, lysis of infected cells and fluorimetric quantification after 
resazurin. Just a trivial failure in one of these steps or a problem with the cell cultures 
would compromise the entire assay, which can take up to one week.  
The advantages of optimizing this assay for drug screening purposes are 
undeniable, compared with the classical methodology, which is laborious and often 
discarded for screening of large numbers of extracts, as referred in I-3.2.. Unfortunately, 
as other methodologies focusing on intracellular amastigotes, the inherited difficulties of 
this model in high-throughput screenings are highlighted, and our objective of 
optimization of a high-throughput assay was not achieved. 
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3. Antileishmanial activity and cytoxicity of halophytic and algal 
extracts 
3.1. Halophytic extracts  
In this work aqueous acetone and dichloromethane extracts from 26 halophyte 
species were evaluated for their in vitro activity against the promastigote stage of L. 
infantum and cytotoxic effect on THP-1 cells. Extracts were applied for 72 h at a 
concentration of 125 µg mL-1 and results are summarized in Table 7.  
Regarding ACE extracts, only that of Calystegia soldanella (syn. Convolvulus 
soldanella) brought about a significant reduction in promastigote viability (down to 57%). 
However, this extract was not selective towards promastigotes, since it also reduced the 
viability of differentiated THP-1 cells (down to 37%). Dichloromethane (DCM) extracts 
were more active towards both cell line and parasites. The application of the 
dichloromethane extracts of I. crithmoides and Spergularia rubra resulted in the lowest 
promastigotes viability (27 % and 17 % with IC50 values of 59.5 ± 0.9 µg mL
-1 and 70.5 
± 1.7 µg mL-1, respectively). However, these extracts were also highly cytotoxic to 
differentiated THP-1 cells: that of I. crithmoides and of S. rubra displaying an IC50 of 
20.3 ± 0.3 µg mL-1 (SI=0.3) and 49.3 ± 0.4 µg mL-1 (SI=0.7), respectively.  
Moreover, the DCM extracts of L. salicaria, Salsola sp., L. monopetalum, S. perennis 
alpini, S. ramosissima and S. vermiculata all presented an interesting feature: they all 
modestely decreased the viability of promastigotes without significantly affecting the 
viability of THP-1 cells.  
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Table 7 Antileishmanial activity and cytotoxicity towards THP-1 cells of acetone and 
dichloromethane extracts of different halophyte species. 
Species Extract 
Viability (%) 
L. infantum THP-1 
Arthrocnemum macrostachyum 
ACE 105.9 ± 1.5 114.1 ± 2.9 
DCM 79.2 ± 0.3*   14.1 ± 0.6* 
Aster tripolium 
ACE 108.6 ± 0.9      81.0 ± 3.4* 
DCM 94.8 ± 0.5      72.4 ± 4.6* 
Calystegia soldanella  
ACE   57.8 ± 4.7*      36.6 ± 0.9* 
DCM  75.5 ± 7.7*      51.5 ± 2.1* 
Centaurium erythraea 
ACE 87.2 ± 3.5      86.9 ± 3.3 
DCM 89.3 ± 1.6 62.3 ± 1.8* 
Cladium mariscus 
ACE 114.7 ± 5.1    126.7 ± 2.7* 
DCM 92.6 ± 1.1    101.9 ± 2.8 
Frankenia laevis 
ACE 126.4 ± 2.7*    176.5 ± 2.7* 
DCM 107.2 ± 2.2      34.1 ± 0.5* 
Frankenia pulverulenta 
ACE 137.1 ± 3.1*    142.2 ± 6.1* 
DCM 88.9 ± 3.8      76.5 ± 1.4* 
Halopeplis amplexicaulis 
ACE 90.4 ± 1.7    120.4 ± 5.5* 
DCM 73.1 ± 6.4* 45.3 ± 1.9* 
Inula crithmoides 
ACE  88.9 ± 0.8      37.8 ± 1.6* 
DCM 26.5 ± 0.7* 10.5 ± 0.3* 
Lactuca sp. 
ACE 102.5 ± 6.5    122.7 ± 4.4* 
DCM    82.8 ± 1.7*    100.5 ± 3.1 
Limoniastrum monopetalum 
ACE  117.6 ± 3.2* 147.1 ± 2.4* 
DCM    82.2 ± 0.8*    101.3 ± 2.1 
Lythrum salicaria 
ACE  143.2 ± 1.7*      84.3 ± 2.9 
DCM  76.0 ± 3.1*    114.0 ± 2.0* 
Mesembrianthemum cristalino 
ACE  106.1 ± 9.9    134.6 ± 4.7* 
DCM  85.4 ± 0.7*    132.1 ± 3.8* 
Panicum repens 
ACE  92.7 ± 4.0    120.9 ± 2.9* 
DCM  97.6 ± 2.9      52.5 ± 0.2* 
Pistacia lentiscus 
ACE  130.6 ± 2.5*    130.6 ± 5.8* 
DCM    89.6 ± 1.9 31.4 ± 0.2* 
Puccinelia sp. 
ACE    88.2 ± 1.8    122.8 ± 5.4* 
DCM    90.2 ± 0.9    111.0 ± 2.9* 
Salicornia fragilis 
ACE  100.0 ± 1.9 151.2 ± 2.9* 
DCM    78.4 ± 4.6*      75.8 ± 1.8* 
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Table 7 Cont. 
Species Extract 
Viability (%) 
L. infantum THP-1 
Salicornia ramosíssima 
ACE 92.0 ± 1.7 151.3 ± 7.6* 
DCM 78.8 ± 1.1* 107.0 ± 2.2 
Salicornia perennis alpini 
ACE 97.3 ± 1.6 114.5 ± 6.1 
DCM 78.2 ± 3.0* 119.7 ± 1.0* 
Salicornia perennis perennis 
ACE 97.1 ± 1.8 143.4 ± 7.3* 
DCM 79.3 ± 1.7*     13.7 ± 0.5* 
Salsola sp. 
ACE 90.7 ± 2.1 79.7 ± 2.1* 
DCM 84.6 ± 1.2* 121.3 ± 3.3* 
Salsola vermiculata 
ACE 100.3 ± 0.7 108.2 ± 5.7 
DCM     64.3 ± 5.3* 105.3 ± 1.6 
Spartina versicolor 
ACE 115.0 ± 1.4* 122.8 ± 1.6* 
DCM 92.4 ± 1.3 125.4 ± 3.0* 
Spergularia rubra 
ACE 89.7 ± 2.7 107.2 ± 4.8 
DCM    16.7 ± 0.5*     29.6 ± 0.2* 
Sporobolus sp 
ACE 100.0 ± 2.9 81.7 ± 3.1 
DCM 98.9 ± 2.3 96.8 ± 3.1 
Typha dominguensis 
ACE 94.9 ± 1.4   134.8 ± 2.7* 
DCM   91.2 ± 0.8     83.9 ± 4.0* 
DMSO    99.8 ± 1.2 100.0 ± 0.2 
Amphotericin B1 n.d.     67.3 ± 4.2 
Pentamidine1 n.d.     12.2 ± 0.1 
Miltefosine1 n.d.   8.0 ± 0.1 
Values represent the mean ± SEM, obtained from at least three independent experiments performed in 
triplicate. n.d. not determined; 1Positive controls; Statistical significance in viability between cells 
containing DMSO (0.5%, v/v) diluted in culture medium and those treated with extracts are indicated as * 
(p < 0.05; Dunnet’s test). 
 
C. soldanella also known as the morning glory and the Prince's Flower is a 
perennial plants that can be found in coastal habitats in temperate regions of the world, 
and has been used for centuries in traditional medicine as a purgative (Pereda-Miranda et 
al., 2010; Takigawa et al., 2011). It belongs to the Convolvulaceae family, which is 
known for biosynthetizing unique secondary metabolites namely resin glycosides 
(Tasdemir et al., 2008). In fact, hapargide and crypthophilic acid C, purified from a 
MeOH extract of the aerial parts of Scrophularia cryptophila, had high activity towards 
L. donovani axenic amastigotes (Tasdemir et al., 2008).  
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It is not surprising that the ACE extracts were poorly active as some authors claim 
that the bioactive compounds towards Leishmania are mainly found in less polar extracts 
(Genovese et al., 2009; Vonthron-Sénécheau et al., 2011). However, extraction with 80% 
ACE is recommended to extract phenolics, since some studies have put forward the 
antileishmanial potential of this group of compounds (Zhao et al., 2006; De Arias et al., 
2012).  
The genus Inula is widely distributed through Africa, Asia and Europe, especially 
in the Mediterranean area. At least 100 species are known and have been extensively used 
in Chinese traditional medicine (Seca et al., 2014). Interestingly, flowers from I. 
crithmoides have been used in traditional medicine to treat several urinary related 
illnesses, but also infectious diseases, such as malaria and tuberculosis (revised by Dos 
Santos, 2009). More recently, mainly due to their ethnopharmacological relevance, the 
chemotherapeutic properties of various Inula species have been investigated, which were 
found to possess cytotoxic, antibacterial, antioxidant and hepatoprotective activities 
(Zhao et al., 2006; Giampieri et al., 2010).  
Plants belonging to the Spergularia genus are found in temperate and subtropical 
regions of all continents, except Antartida. Although they have been used in traditional 
medicine of Kuwaiti and Mediterranean region as a remedy for kidney stones, other 
related kidney illnesses, and as a diuretic (Middleditch and Amer, 1991; González-Tejero 
et al., 2008), few biological activities have been reported for S. rubra. However, water 
extracts obtained from infusion of the whole plant have significantly reduced the glucose 
blood levels in experiments with diabetic rats (Bnouham et al., 2002) and its aerial parts 
have antiradical, antidiabetic and anticholinesterase activities (Vinholes et al.,2011). 
So far, to our knowledge, there is no report on the antileishmanial activity or 
cytotoxicity for S. rubra and I. crithmoides. Moreover, to the best of our knowledge, there 
are no reports of the antileishmanial activity in halophytes. 
According to Cos et al. (2006) natural extracts for anti-infective assays are 
considered relevant when they exhibit IC50 values lower than 100 μg mL
-1, taking the 
selectivity index into account (Cos et al., 2006). In this study, besides its good 
antileishmanial activity, the high cytotoxicity observed makes these extracts unappealing 
for further investigations, since the selectivity indexes obtained are low (<1; Table 8).  
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Table 8 Antileishmanial activity (promastigotes), cytotoxicity (IC50
 values) and 
selectivity index (SI) of acetone and dichloromethane extracts of S. rubra and I. 
crithmoides. 
Species Extract 
IC50 values (µg mL
-1) 
SI 
L. infantum  THP-1  
I. crithmoides 
ACE >125 n.d. n.d. 
DCM 59.5 ± 0.9a 20.3 ± 0.3a 0.3 
S. rubra 
ACE >125 >125 n.d. 
DCM 70.5 ± 1.7b 49.3 ± 0.4b 0.7 
Amphotericin B 0.54 ± 0.0c >125 >231.5 
Miltefosine 14.6 ± 0.6d  7.7 ± 0.1c 0.5 
Pentamidine 0.81 ± 0.0c 52.7 ± 1.9b 65.1 
n.d., not determined; Values represent the mean ± SEM of three independent experiments performed in 
triplicate. Values followed by different letters are significantly different (p < 0.05; Tukey’s test). 
 
However, it is worth mentioning that the SI of the DCM extract of S. rubra (0.7) 
was similar to that of miltefosine (0.5), an established oral drug used in leishmaniasis 
treatment and as positive control in this study. In contrast, it was substantially lower than 
that of the other positive controls, namely AmB and pentamidine. 
It is important to emphasize the relative significance of the cytotoxicity values 
and the selectivity indexes obtained. S. rubra and I. crithmoides were poorly selective. 
However, it may be considered that an extract is a mixture of compounds. Thus, it is 
difficult to discriminate, without a bioguided fractionation study, if the high cytotoxicity 
and antileishmanial activities observed for the same extract are produced by the same or 
different compound(s) present (De Toledo et al., 2014). Thus, further research on this 
species potential must be considered, because the bioactive compounds may in fact be 
selective upon fractionation. 
Despite the low activity towards promastigotes and/or high toxicity on 
differentiated THP1 cells, additional studies should be performed in order to fully explore 
the antiparasitic potential of the halophytes species under study. 
Firstly, in this work, only two solvents were used, namely acetone and 
dichloromethane. Since an extract is a mixture of compounds and considering that there 
is no solvent that will isolate all its constituents, perhaps the compounds of interest were 
not extracted by the solvents used, or were only present in low concentrations in the 
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mixture. For example, the S. rubra acetone extract did not present any antileishmanial or 
cytotoxicity, although the DCM extract was significantly active for both the parasites and 
mammalian cells. Most probably, in this case, the bioactive compounds are not soluble in 
ACE, but in DCM. Thus, in future work, other solvent systems may be tried to evaluate 
the antileishmanial activity of these species. 
Secondly, only the aerial parts of halophytes were extracted in this study. As the 
roots of halophytes have already been described as sources of bioactive compounds, these 
may be included in additional screening efforts (Rasheed et al., 2013). 
Lastly, cold extraction was used in this study. However, previous results obtained 
by our group indicate that the extraction method may influence the isolation of 
compounds with antileishmanial activity. In future studies, hot extractions may be 
performed in order to collect higher ammounts of the compound(s) of interest, since these 
may be lost in the process. In fact, it was already observed significant variations in the 
percentage of yield of the compounds of interest obtained between plant species extracted 
with the same solvent, between solvents used for the same species, and also between the 
extraction methods applied, which affects the overall bioactivities tested (Bouaziz et al., 
2009). 
Moreover, alternative studies with the non-active and non-toxic extracts could 
also be performed. Although inactive towards both cellular lines, these may be able to 
modulate the macrophages response preventing L. infantum promastigotes infection by 
increasing reactive oxygen species and nitric oxide production, for instance. As 
Leishmania parasites are able to evade the immune defense arsenal by inhibiting ROS 
and NO production and increasing the activity of suppressive cytokines, extracts 
enhancing the response of macrophages may be useful in the fight against infection (Shio 
and Olivier, 2010). After infection with L. amazonensis promastigotes of pre-treated 
macrophages with the crude aqueous extract of the palm tree Syagrus coronate (33 µg 
mL-1), a decrease of 70.4% in the association index (number of parasites that successfully 
infected the macrophages) as well as an increase of 158.3% of NO production, in 
comparison to untreated cells, was observed (Rodrigues et al., 2011). Likewise, after 
infection with L. amazonensis of pre-treated macrophages with linalool-rich essential oil 
extracted from Croton cajucara (15 ng mL-1), the association index was 50% lower and 
NO production was 220% higher (Rosa et al., 2003). Also, the pre-incubation of 
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macrophages with Aloe vera leaf exudate has led to activation of macrophages through 
increased ROS production, which enhanced the antileishmanial activity of the exudate 
(Dutta et al., 2007).  
Interestingly, Arevalo et al. (2001) have shown that Imiquimod, acts as a 
modulator of the immune response by increasing the production of cytokines such as IFN-
γ and interleukines such as TNF. Moreover, in vitro studies revelead its capacity to 
eliminate Leishmania amastigotes by increasing the production of NO. Furthermore, 
when a combined imiquimod plus meglumine antimonate therapy was applied to 12 
patients with CL, whom were not responding to meglumine antimonate therapy earlier, 
90% of those were cured after 6 months (Arevalo et al., 2001). 
Taken together, these studies suggest that the study of the macrophage activation 
may be an alternative pathway in the search for bioactive substances with 
pharmacological properties, which may be useful tools in the battle against leishmaniasis. 
3.2. Algal extracts 
Concerning the antileishmanial activity of macroalgae from the Cystoseira genus, 
21% of the extracts tested were active towards the promastigotes of L. infantum. The most 
interesting extracts were the HEX and DCM extracts of C. tamariscifolia and the DCM 
extract of C. usneoides with IC50 values of 31.2 ± 0.9, 29.8 ± 0.5 and 33.6 ± 0.6 µg mL
-1, 
respectively. Yet, their high cytotoxicity towards the mammalian cell line makes both 
extracts poorly selective (SI of 1, 0.7 and 0.4, respectively). 
Moreover, the HEX extracts of C. baccata and C. barbata displayed moderate 
activities, with IC50 values of 94.1 ± 1.5 µg mL
-1 and 78.7 ± 3.2 µg mL-1, respectively 
(Table 9). However, the HEX extract of C. barbata also revealed mild cytotoxicity, with 
an IC50 value of  60.9 ± 2.0 µg mL
-1 and consequently, the SI value was lower than 1. In 
summary, the HEX extract of C. baccata was the most selective extract. Since the 
maximum concentration tested was 125 µg mL-1, the SI is higher than 1.32. 
The cytotoxicity of the macroalga C. tamariscifolia is extensively described, using 
solvents of different polarities (Abourriche et al., 1999; Ainane et al., 2014). Likewise, 
C. tamariscifolia is a proven rich source of anti-proliferative compounds. Hence, the 
activity of its extracts has been previously demonstrated towards Daudi, Jurkat, K562, 
SUP-T1, PF-382 and THP-1 cell lines (Zubia et al., 2009; Vizetto-Duarte et al., 2012). 
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At 125 µg mL-1, the HEX and ether extracts of C. tamariscifolia decreased the viability 
of THP-1 cells to 14.3±0.6 and 14.9 ± 0.9 µg mL-1, respectively (Vizetto-Duarte et al., 
2012). In our study, at this concentration the HEX and DCM extracts of this species 
decreased the viability of THP-1 macrophages to 18.6 ± 0.6 and 17.0 ± 0.5%, respectively 
(data not shown). Thus, the results obtained are in agreement with the published works 
mentioned above. 
The antileishmanial activity of C. tamariscifolia and C. baccata collected in the 
south coast of United Kingdom were evaluated using axenic amastigotes of L. donovani, 
and both presented promising IC50 values, below 10 µg mL
-1 (Spavieri et al., 2010). 
However, the ether and chloroform extracts of C. tamariscifolia collected in Morocco, 
presented IC50 values towards L. infantum promastigotes above 100 µg mL
-1 (Ainane et 
al., 2014). Likewise, the hexane and ether extracts of C. baccata from the Portuguese 
coast, exhibited remarkable IC50 values against L. infantum promastigotes with IC50 
below 8 µg mL-1 (Bruno de Sousa et al., 2012). 
Interestingly, the MeOH extracts of C. barbata collected from the Black Sea and 
the Marmara Sea displayed different antileishmanial activities towards L. donovani 
amastigotes with IC50 values of 23.46 and 69.98 µg mL
-1, respectively (Süzgeç-Selçuk et 
al., 2010). No cytotoxicity against L6 cells were observed at the maximum concentration 
tested of 90 µg mL-1 (Süzgeç-Selçuk et al., 2010). 
In this study, the HEX and DCM extracts of C. tamariscifolia presented high 
antileishmanial activity towards L. infantum promastigotes, with IC50 values below 35 µg 
mL-1, while the HEX extracts of C. barbata and C. baccata presented IC50 values between 
75-95 µg mL-1. Undoubtedly, these 3 species are endowed with compounds able to kill 
Leishmania parasites, as confirmed by others authors.  
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Table 9 Antileishmanial activity and cytotoxicity (IC50, µg mL
-1) of extracts of 




IC50 values (µg mL
-1) 
SI 
L. infantum  THP-1  
C. baccata 
Hex 94.1 ± 1.5a >125 >1.32 
DCM >125 n.d. - 
MeOH1 >125 >125 - 
MeOH2 >125 >125 - 
C. barbata 
Hex 78.7 ± 3.2b 60.9 ± 2.0a 0.8 
DCM >125 n.d. - 
MeOH >125 >125 - 
C. humilis 
Hex >125 >125 - 
DCM >125 >125 - 
MeOH1 >125 >125 - 
MeOH2 >125 >125 - 
C. nodicaulis 
Hex >125 n.d. - 
DCM >125 >125 - 
MeOH1 >125 >125 - 
MeOH2 >125 >125 - 
C. tamarascifolia 
Hex 31.2 ± 0.9c 30.9 ± 0.4b 1 
DCM 29.8 ± 0.5c  19.9 ± 0.5c 0.7 
MeOH1 >125 n.d. - 
MeOH2 >125 >125 - 
C. usneoides 
Hex >125 n.d. - 
DCM 33.6 ± 0.6c 12.6 ± 0.4d 0.4 
MeOH1 >125 n.d. - 
MeOH2 >125 >125 - 
Amphotericin B 0.2 ± 0.0d  >125 >625 
Miltefosine 12.7 ± 1.8e  9.0 ± 0.5d 0.7 
Pentamidine 0.5 ± 0.1d 68.2 ± 1.5e 136.4 
n.d., not determined; Values represent the mean ± SEM of three independent experiments performed at 
least in duplicate. Values followed by different letters are significantly different (p < 0.05; Tukey’s test). 
 
Previous studies focusing on the chemical bioactive molecules from species 
belonging to the Cystoseira genus have identified mainly diterpenoids, meroditerpenoids, 
phlorotannins and sterols (Mokrini et al., 2008; Mighri et al., 2009). Mainly 
meroditerpenoids have been isolated from C. baccata (Mokrini et al, 2008), halogenated 
hydrocarbons and sterols from C. barbata (Milkova et al., 1997) and 
phloroglucintriacetates, phlorotannins and meroditerpenoids from C. tamariscifolia 
(Bennamara et al., 1999; Lopes et al., 2012). The latter two were also tested for antifungal 
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and antibacterial activities.  However, no studies reporting the antileishmanial activity of 
compounds isolated from these species have been found in the literature. 
The dispair antileishmanial activities observed between the activity of the crude 
extracts of our study and others for this three macroalgae, may be related to the different 
Leishmania species or strains, parasite stages, solvents used and extraction methods 
applied. For example, a diterpene compound isolated from the macroalga Canistrocarpus 
cervicornis exhibited an IC50 value of 12.0 μg mL
-1 towards the axenic amastigotes of L. 
amazonensis. Still, towards the promastigote and intracellular amastigote forms the IC50 
values decreased to 2.0 μg mL-1 and 4.0 μg mL-1, respectively (Dos Santos et al., 2010). 
Moreover, the location and period of the biomass collection influences quality and the 
quantity of the secondary metabolites present in it, resulting in differences in the 
bioactivities obtained (Spavieri et al. 2010b; Vonthron-Sénécheau et al. 2011). As an 
example, C. barbata collected in two different locations provided different 
antileishmanial activities (Süzgeç-Selçuk et al., 2010). 
Even the screening method applied may give rise to different IC50 values, such as 
the resazurin method which has been pointed out as more sensitive than the MTT assay 
in the assessment of the effect of drugs (Hamid et al., 2004).  
Interestingly, the comparison of the antibacterial activity between fresh and dried 
algae demonstrated that the tested organisms were more sensitive when fresh algae were 
used, suggesting that the active compounds may be volatile and were lost during the 
drying process (Tuney et al., 2006). Likewise, the storage conditions of samples may 
influence the bioactivities obtained through the loss of valuable compounds (Srivastava 
et al., 2007).  
Besides C. baccata, C. barbata and C. tamariscifolia, only two panel 
presentations focus on the antileishmanial potential of C. usneoides, C. humilis and C. 
nodicaulis, with similar results in comparison to this work (Bruno de Sousa et al., 2012; 
2014). 
However, phlorotannins extracted from the brown macroalgae C. usneoides 
collected in Peniche, Portugal, exhibited strong antifungal properties combined with a 
significantly decrease in the amount of ergosterol, the main sterol of Leishmania 
membrane (Lopes et al., 2013). Thus, the strong antileishmanial activity observed in this 
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study for the dichloromethane extract of C. usneoides could be related to the presence of 
compounds targeting ergosterol.  
The study of the Cystoseira extracts here presented are currently undergoing 
bioguided fractionation studies in an ongoing PhD project. In this context, the most 
interesting extracts, as the C. baccata’s, are being studied for their antileishmanial activity 
with the ultimate goal of isolating the bioactive compounds. 
As referred for halophyte extracts in II-3.2., a careful interpretation of the 
selectivity indexes of C. tamariscifolia, C. usneoides and C. barbata active extracts may 
be needed due to the diversity of compounds present in the latter. Fractionation of these 
extracts may unravel the specificity of the selectivity indexes observed, since synergistic 
effects between compounds may also account for the activity observed. As discussed 
earlier, it would be interesting to evaluate if these extracts remain active towards the 
intracellular model of Leishmania. Furthermore, the potential of the non-active extracts 
of macroalgae, as enhancers of the macrophage activation, could be pursued in further 
studies as suggested for the halophytic extracts.  
3.2.1. Effect of Cystoseira extracts on L. infantum promastigote morphology 
Because the HEX extracts of C. baccata and C. barbata displayed low 
cytotoxicity against THP-1 cells, but were still active towards L. infantum promastigotes, 
a microscopic analysis of the their leishmanicidal effects was performed. 
Since the HEX extract of C. baccata at the maximum concentration tested 
exhibited mixed morphology of the affected parasites, only the image acquired of the 
effect of C. barbata HEX extract is presented (Figure 19D). For comparison purposes, 
the HEX extract of C. nodicaulis, which did not presented activity, was included (Figure 
19C). 
At 125 µg mL-1, the extract of C. barbata significantly reduced the parasite’s 
viability to 37% and in parallel induced deep morphological changes on promastigote 
cells, as observed by light microscopy.  
 
 




Figure 19 Effect of C. barbata and C. nodicaulis HEX extracts (125 µg mL-1, 48h) on 
the morphology of L. infantum promastigotes: A, Control cells cultured in RPMI medium; 
B, positive control, AmB (IC50); C, C. nodicaulis; D, C. barbata. Bright field images, 
scale bar corresponds to 5 µm. 
Control cells have a normal shape and both kinetoplast and nucleus are well 
distinguished. C. barbata induced considerable changes in parasites morphology such as 
cell shrinkage accompanied with an abnormal round shape, dense cytoplasm and also, 
some parasites presented loss of the flagella. Moreover, the loss of parasite’s motility was 
evident. 
As expected, since C. nodicaulis was inactive towards L. infantum promastigotes, 
it did not cause any clear morphological changes or loss of mobility, in comparison with 
control cells. 
The HEX extract of C. baccata caused less pronounced but similar morphological 
changes than the ones induced by C. barbata extract (data not shown). Affected parasites 
had round to oval shape, with short flagella and were not motile. Nevertheless, some 
parasites exhibiting normal morphology were observed and a few still presented normal 
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motility. This can be due to the fact that the IC50 value of C. baccata is higher than that 
of C. barbata. 
Similarly, the positive control was tested at its IC50 value. The majority of cells 
presented alterations in the membrane of the cell, which may be due to the fact that AmB 
interacts with the main sterol, namely ergosterol, present in the Leishmania parasites 
membrane, leading to membrane disruption, as discussed before in I-1.4. 
The observed alterations were also reported in L. tropica promastigotes treated 
with propolis samples (Duran et al., 2008; Ozbilge et al., 2010), in L. amazonensis 
promastigotes treated with ethanolic extracts of Azadirachta indica (Carneiro et al., 2012) 
and L. major promastigotes treated with Allium sativum extract (Khademvatan et al., 
2011). 
As these are preliminary observations, future work involving bioguided 
fractionation and ultrastructural analysis of promastigote morphology could unravel the 
mechanisms of action of the selected fractions or compounds, in combination with other 
methodologies for this purpose (Neto et al., 2011).  
3.3. Evaluation of the effect of the extracts on the amastigote-macrophage 
model 
In the context of this work, the antileishmanial activity of C. barbata and C. 
baccata HEX:DCM extracts against intracellular amastigotes of L. infantum was 
evaluated. Similarly, the toxicity of the extracts was assessed towards THP-1 
macrophages, to determine the selectivity index. 
Samples of these two species were extracted by using a hot soxhlet-based system 
to increase the yield of bioactive compounds. As mentioned in III-3.2., based on previous 
results obtained in the MarBiotech group, this extraction methodology was more efficient 
than the cold centrifugation extraction technique in achieving higher amounts of the 
compounds of interest (Oliveira et al., 2014). 
Having in mind the latter results concerning the promastigotes primary screen, as 
these two species have presented moderate activity along with lower cytotoxicity to the 
mammalian macrophages, its activity was tested on the amastigote-macrophage system, 
using the previously optimized direct counting method (Figure 20). 




Figure 20 THP-1 infected cells used for the assessment of the activity of C. baccata and 
C. barbata extracts by direct counting method previously optimized (Original from 
Oliveira, M.). Scale bar corresponds to 10 µm. 
In contrast with the results observed for promastigotes using cold extracts, the C. 
barbata extract was the most interesting, with an IC50 value of 15.1 ± 2.9 µg mL
-1, while 
that of C. baccata was less active with an IC50 of 50.2 ± 2.6 µg mL
-1. As a consequence 
of the cytotoxicity determined for these extracts, SI of C. barbata and C. baccata were 
greater than 8.3 and 2.5, respectively (Table 10). 
Table 10 Antileishmanial activity towards intracellular amastigotes (IC50, µg mL
-1), 
cytotoxicity (IC50, µg mL
-1) and selectivity indexes (SI) obtained for C. baccata and C. 
barbata extracts.  
Species 
IC50 values (µg mL
-1) Selectivity 
index   
(SI) 
L. infantum THP-1 
C. baccata 50.2 ± 2.6a >125 >2.5 
C. barbata 15.1 ± 2.9b >125 >8.3 
Amphotericin B   0.1 ± 0.0b >125 >1250 
Miltefosine   0.4 ± 0.1b 9.0 ± 0.5 22.5 
Values represent the mean ± SEM obtained from three independent experiments with at least two replicates 
each. * represents the positive controls. Values followed by different letters are significantly different (p < 
0.05; Tukey’s test). 
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Interestingly, when tested towards the promastigote form, C. baccata Hex:DCM 
extract was more active than a similar extract of C. barbata (IC50, 30.6 ± 2.8 and  74.7 ±  
6.0 µg mL-1, respectively; Oliveira et al. 2014). However, towards the amastigote-
macrophage system, C. barbata was clearly the most interesting extract, with a selectivity 
index greater than 8.3. In fact, miltefosine was not selective towards the promastigotes 
(SI = 0.5) either; conversely, its selectivity towards amastigotes was high (SI = 22.5). 
These results highlight the relevance of the in vitro model used for efficient research of 
natural products with antileishmanial activity. Additionally, the presence of the 
macrophage may influence the effectivity of the extract to affect the intracellular parasites 
as discussed in I-3.1. 
Although the SI of the positive control AmB is 156 fold greater than that of C. 
barbata, the SI of miltefosine is only 3 fold greater. However, and as discussed above in 
III-3.1., considering that an extract is a mixture of compounds, the fractionation of the 
extract and further isolation of the bioactive compound may lead to increased selectivity. 
It would be interesting to elucidate the mechanisms of action of the selected active 
fractions or compound(s) as well as the morphological and ultrastructural changes 
induced in parasites in future lines of research.  Moreover, other mammalian cellular lines 
should be tested to confirm the cytotoxic values obtained, including the peritoneal 
macrophages, as a useful indication for additional in vivo studies. 
To our knowledge, this is the first report of C. barbata and C. baccata effect on 
the in vitro infection of THP-1 macrophages with L. infantum parasites. 
In summary, and despite the low antileishmanial activities displayed by the 
majority of macroalgae in this study, some of the species tested may be considered as 
interesting sources of bioactive compounds against L. infantum parasites, namely C. 
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Current available drugs for human leishmaniasis treatment exhibits several 
disadvantages such as high costs, toxicity, long-term periods of parental administration 
for some drugs, variation in intrinsic sensitivity between Leishmania species and 
development of drug resistances (Croft & Coombs, 2003; Singh et al., 2012).  
In the last decades, marine natural products have been investigated for their 
antileishmanial compounds and some promising results have been achieved. However, 
the drug screening for natural products with antileishmanial properties exhibits several 
difficulties mainly due to the lack of standardization of the screening methodologies and 
parasite in vitro models used. 
In this work the mammalian cell infection model was established using metacyclic 
promastigotes of L .infantum and differentiated THP-1 cells as host cells. This model was 
used for optimization of the direct counting method conditions for further testing of the 
most interesting extracts towards the clinical relevant stage of the parasite. 
The obvious drawbacks of the direct counting method were the main 
encouragement for our efforts to optimize a methodology that would enable the screening 
of large numbers of extracts by observing their effect on the amastigote-macrophage 
system. Thus, the parasite rescue assay, a methodology involving the lysis of infected 
cells with consequent liberation of the amastigotes, was, and still is, a possible avenue of 
research in order to implement a laboratory procedure that could attain that goal. An 
encouraging result is that the optimal lysis conditions were established. The fluorescence 
measurements, however, still needd to be fully optimized in the near future. To address 
the optimization of this final step, both time of incubation and concentration of resazurin 
must be studied until conditions optimal for assessing the effect of the extracts are 
established. In spite of its challenges and pitfalls, the unquestionable advantages of this 
method should be not ignored. Hence, if developed further, it might prevent the discarding 
of promising extracts upon evaluation of their activity towards the extracellular form of 
the parasite, namely promastigotes. 
Furthermore, the antileishmanial activity of halophyte and macroalgae extracts 
were investigated, and the results indicate that some of these organisms may present 
compounds with antileishmanial activity. S. rubra and I. crithmoides DCM extracts as 
well as the HEX and DCM extracts of the macroalgae C. tamariscifolia and the HEX 
extract of C. usneoides were the most active towards L. infantum promastigotes, yet 
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poorly selective. The HEX extract of the macroalgae C. baccata displayed the higher 
selectivity index of all the extracts tested. Although the SI were not very interesting, 
further investigation on these active species should be reconsidered, having in mind the 
possibility of distinct compounds being responsible for the antileishmanial and cytotoxic 
activities observed, and also that the activity may be specific to each parasite stage. Thus, 
more interesting results are possible to be achieved. 
Despite the fact that the majority of extracts were inactive towards the 
promastigote form of L. infantum, it should not be concluded that these species do not 
contain bioactive compounds. In future work, other solvents, more efficient extraction 
methods or even other halophyte parts should be used in an attempt to extract the 
compounds of interest. Moreover, C. baccata and C. barbata HEX:DCM hot extracts 
showed higher selectivity against Leishmania intracellular amastigotes, reinforcing the 
importance of both the extraction technique and the in vitro model used. C. barbata 
displayed the most promising selectivity (SI = 8.3) in comparison to the positive controls, 
even though the bioactive(s) compound(s) are mixed with other inactive molecules within 
the extracts used. 
Last but not least, these results may encourage additional research on bioactive 
compounds from C. barbata. Thus, the search for novel bioactive compounds should be 
pursued not only via bioguided fractionation, but also by using peritoneal macrophages 
as the mammalian model. This would yield more reliable results regarding cytotoxicity, 
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